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ABSTRACT
DETECTION OF ANEUPLOIDY FOR CHROMOSOMES 7 AND 8
USING FLUORESCENCE IN SITU HYBRIDIZATION IN
PATIENTS WITH APLASTIC ANEMIA AND SEQUENCING
OF THE MITOTIC CHECKPOINT GENE hBUBl
Laura Jane Aridgides
Old Dominion University, 2001
Director: Dr. Christopher Osgood

Aplastic anemia
marrow failure.

(AA) is characterized by complete bone

Progression to myelodysplastic syndromes

(MDS) and acute nonlymphocytic leukemia (ANLL) occurs
frequently.

At the time of transformation,

abnormalities are common.

cytogenetic

Detection of cytogenetic

abnormalities prior to leukemic transformation may indicate
future disease progression.

Karyotype analysis is the

current method of choice to evaluate chromosome
aberrations.

However,

fluorescence in situ hybridization

(FISH) is more sensitive in detecting these abnormalities.
hBUBl, a mitotic spindle checkpoint gene, was shown to be
mutated in two colorectal cancer cell lines with high
levels of aneuploidy

(Cahill, et al., 1998).

theoretically possible,

Although

conclusive evidence does not

currently exist establishing a link between aneuploidy
levels and mutations within a mitotic spindle checkpoint

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

gene.

hBUBl is the most characterized of the mitotic

checkpoint genes.
FISH was used to detect cytogenetic abnormalities for
chromosomes 7 and 8 in bone marrow samples from patients
with AA.

In addition, ribonucleic acid (RNA) from all

patient samples also underwent hBUBl-specific reverse
transcription polymerase chain reaction (RT-PCR) , followed
by sequencing of the RT-PCR product.

Statistical analyses

were performed on FISH and sequencing results.

Additional

samples from patients with a variety of bone marrow
disorders also underwent hBCTBI-specific RT-PCR and
sequencing without FISH analysis.
Seven patient samples out of 4 6 (15.2%) showed elevated
levels of aneuploidy for chromosomes 7, 8, or both.

Four

of the seven samples showed abnormalities previously
undetected by a karyotype analysis.

This indicates that

FISH analysis is approximately twice as sensitive as a
karyotype analysis, and may assist in earlier diagnosis and
proper treatment of patients with AA.

Statistical analysis

showed an increased level of monosomy 8 in African-American
males.

The age of the patient and responsiveness to

treatment did not correlate with the level of aneuploidy.
Results from the h-BUBl-specif ic RT-PCR and sequencing were
inconclusive due to the high probability of Taq-induced PCR
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artifact, however there was no apparent correlation between
the presence of aneuploidy and the sequencing results.
Seventy-eight to 85% of all patient samples analyzed did
not amplify any hBDBl-specific RT-PCR product.
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A BBREVIATIONS
A A = aplastic anemia
AL = acute leukemia
AML = acute myeloid leukemia
Amp = ampicillin
ANLL = acute nonlymphocytic leukemia
APC = anaphase promoting complex
ATG = antithymocyte globulin
BUB = budding uninhibited by benzimidazole
CD = cluster of differentiation
CDC = cell division cycle
cdk = cyclin-dependent kinase
cDNA = complimentary DNA
CFU = colony-forming unit
CIN = chromosomal instability
CKI = cyclin-dependent kinase inhibitor
CMML = chronic myelomonocytic leukemia
CsA = cyclosporin A
DAPI = 4',6-diamidino-2-phenylindole
DNA = deoxyribonucleic acid
EDTA = disodium ethylenediamine tetraacetate
Epo = erythropoietin
FA = Fanconi's anemia
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FAB = French., American, and British
FISH = fluorescence in situ hybridization
gal = galactosidase
G-CSF = granulocyte colony-stimulating factor
GM-CSF = granulocyte-macrophage colony-stimulating factor
GPI = glycosylphorphatidylinositol
GVHD = graft versus host disease
IL = interleukin
INF = interferon
IPTG = isopropyl {3-D-thiogalactopyranoside
LB = Lennox broth
MAD = mitotic arrest deficient
MBG = molecular biology grade
M-CSF = macrophage colony-stimulating factor
MDS = myelodysplastic syndromes
MI = mitotic index
M IN = microsatellite instability
MPF = maturation (M phase) promoting factor
MPS = monopolar spindle
MTOC = mictotubule organizing center
Nal = sodium iodide
NK = natural killer cell
PBS = phosphate buffered saline
PCR = polymerase chain reaction
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X

PNH = paroxysmal nocturnal hemoglobinuria
RA = refractory anemia
RAEB = refractory anemia with excess blasts
RAEB-t = refractory anemia with excess blasts in
trans formation
RARS = refractory anemia with ringed sideroblasts
Rb = retinoblastoma
RNA = ribonucleic acid
RT-PCR = reverse transcription polymerase chain reaction
SAA = severe aplastic anemia
SCF = stem cell factor
TAE = Tris-acetate-EDTA
TBE = Tris-borate-EDTA
TE = Tris-EDTA
TGF = transforming growth factor
t-MDS = therapy-related myelodysplastic syndromes
TNF = tumor necrosis factor
TPO = thrombopoietin
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1

CHA P T E R I
INTRODUCTION

HEMATOPOIESIS

Overview
Hematopoiesis

is defined as "the formation and

development of blood cells involving both proliferation and
differentiation from stem cells
2001)

(Online Medical Dictionary,

The stem cells necessary for successful

hematopoiesis begin to form in the yolk sac during early
gestation, and migrate to the liver and the spleen before
settling within the bone marrow.

It is in the bone marrow

that the majority of hematopoiesis occurs in healthy
individuals

(Sullivan, 2001).

However, most of the stem

cells within the bone marrow are in a quiescent state
(Jordan and Van Zant, 1998; Sullivan, 2001).

A portion of

the cells undergo self-renewal, but only a tiny fraction of
the cells are differentiating at any given time (Sullivan,
2001) .

The model for this dissertation is the journal Cell.
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Stem Cell Differentiation
All cells differentiate from a totipotent stem cell
(Peterson,

1995; Sachs, 1996) .

The totipotent stem cell

has the potential to travel down the myeloid
differentiation pathway, the lymphoid differentiation
pathway, or to undergo self-renewal
Sullivan,

2001).

(Klumpp, 2001;

The mechanism that determines the cell's

fate is unclear, but it is thought to be either stochastic
(random) or induced by external stimuli (cell to cell
interactions and/or cytokines)

(Enver et a l ., 1998) .

When

the decision is made to differentiate, the stem cells
become multipotent myeloid or lymphoid stem cells.

The

multipotent stem cells give rise to progenitor cells called
colony-forming units

(CFU)

(Klumpp, 2001; Sullivan,

2001).

The myeloid pathway is further subdivided into the
erythroid, megakaryocytic and phagocytic branches.

The

erythroid pathway ends in the formation of erythrocytes,
and the megakaryocytic pathway ends in the formation of
platelets.

The phagocytic pathway subdivides even further

into granulocytic and monocytic pathways.

The granulocytic

pathway divides once more into the neutrophilic,
eosinophilic and basophilic pathways, which end in the
formation of neutrophils,

eosinophils and basophils,
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respectively.

The monocytic pathway ends in the formation

of macrophages

(Sullivan, 2001).

The lymphoid pathway is also subdivided into the B cell
pathway, the T cell pathway and the non-B, non-T cell
pathway.

The B cell pathway ends in the formation of B

cells, and the T cell pathway ends in the formation of T
cells.

The non-B, non-T cell pathway ends in the formation

of natural killer (NK) cells
2001)

(Figure 1).

(Peterson, 1995; Sullivan,

The cluster of differentiation (CD)

antigens presented on each cell's surface can assist in
identification of the different cell types

(Sears,

1997) .

The Role of Cytokines in Hematopoiesis
Cytokines can act as growth factor hormones that
orchestrate the production of cells during hematopoiesis.
Each cytokine acts upon one or more specific cell types.
To elicit a response,

the cell must have a receptor

specific for the cytokine.

There are a wide variety of

cytokines including, but not limited to: erythropoietin
(Epo), thrombopoietin

(TPO), granulocyte-macrophage colony-

stimulating factor (GM-CSF) , granulocyte colony-stimulating
factor

(G-CSF), macrophage colony-stimulating factor (M-

CSF), stem cell factor (SCF), tumor necrosis factor alpha

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Erythroid progenitor

Figure 1. Overview of Hematopoiesis,
Interactions.

Erythrocyte

Including Cytokine

Photograph taken from http://www.whfreeman.com/kuby
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(TNF-a) , transforming growth factor beta (TGF-0) , and a
variety of interleukins

(IL)

(Klumpp, 2001; Moqattash and

Lutton, 1998; Sachs, 1996; Sullivan, 2001).
cytokines thiat induce hematopoiesis

There are

(such as GM-CSF and IL-

2) and there are cytokines that inhibit hematopoiesis
as TGF-3, IIL-10 or interferon gamma
Lutton,

1998; Sachs, 1996).

(such

(INF-y) ) (Moqattash and

The mechanism of stimulation

or inhibition may be direct or indirect, and may involve
multiple cytokines acting together to achieve the final
outcome

(Mocqattash and Lutton,

stem cells,

1998) .

A triad comprised of

cytokines and the bone marrow stroma works

together to achieve hematopoiesis
Moqattash an d Lutton,

(Enver et al.,

1998; Orkin,

1998;

1996; Sullivan,

2001).

The hematopoietic progenitor cells adhere to the bone
marrow stroma enabling them to receive cytokine signals
from the stroma.

Leukemic cells also rely on adhesion to

the stroma matrix to increase survival and reduce the
likelihood o f apoptosis
and Lutton,

(Greer and Kinney, 1993; Moqattash

1998; Sachs, 1996).

A defect in any component

of the hematopoietic triad creates the potential for bloodrelated diseases,
1998; Sachs,

such as leukemia

(Moqattash and Lutton,

1996).

It is of interest to report on some of the more common
cytokines an d their actions on normal cell growth; however,
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a complete review is beyond the scope of this manuscript.
Epo is involved in erythropoiesis by stimulating
differentiation of erythroid colony-forming units

(CFU-E)

and increasing red blood cell production (Moqattash and
Lutton,

1998; Sullivan, 2001) .

TPO stimulates

megakaryocytes and, as a result, increases the number of
platelets

(Moqattash and Lutton,

1998).

GM-CSF in

combination with SCF can stimulate various hematopoietic
pathways.

G-CSF stimulates the differentiation of

leukocytes.
monocytes.

M-CSF stimulates the differentiation of
A variety of IL cytokines can assist other

cytokines in the stimulation or inhibition of various
hematopoietic pathways
199 6).

(Moqattash and Lutton,

1998; Sachs,

There is a tremendous complex cytokine network that

has a direct impact on hematopoiesis, of which all
functions are not yet known or completely understood.
Cytokines have been implicated in leukemic
transformation, which is characterized by uncontrolled cell
growth.

This can be due to inhibition of apoptosis or an

increase in hematopoiesis

(Israels and Israels, 1999;

Wickremasinghe and Hoffbrand,
involved in both apoptosis

1999).

Since cytokines are

(cell death) and hematopoiesis

(inducing cell growth and differentiation), it can be
inferred that abnormal cytokine production may contribute

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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to the formation of cancer (Israels and Israels,
Moqattash and Lutton,

1998).

For example,

1999;

it has been

reported that IL-8 can stimulate bcl-2 expression in cells
from patients with B-cell chronic lymphocytic leukemia.
Increased levels of bcl-2 help protect the cancerous cells
from apoptosis (an increased level of bcl-2 has also been
reported in patients with myelodysplastic syndromes
(Israels and Israels, 1999; Moqattash and Lutton,
Sachs, 1996; Wickremasinghe and Hoffbrand,

(MDS))

1998;

1999).

Cytokine

effects on leukemic cells are incredibly variable and have
been shown to elicit different responses in different
patients

(Marsh, 2000; Moqattash and Lutton,

1998).

Cytokines have recently been investigated for clinical
use in patients with hematological disorders, the caveat
being that cytokines can also decrease the effectiveness of
some anticancer agents by inhibiting apoptosis
2000; Moqattash and Lutton,

1998; Sachs,

Wickremasinghe and Hoffbrand, 1999).

(Marsh,

1996;

Studies showed that

patients with MDS treated with G-CSF and Epo resulted in an
increase in hematopoiesis.

On the other hand, treatment

with growth factors can also inhibit apoptosis of leukemic
cells, which is manifested as a poor response rate to some
chemotherapeutic agents

(Moqattash and Lutton,

1996).

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

1998; Sachs

8

BONE MARROW FAILURE SYNDROMES

Although aplastic anemia (AA) is the primary focus of this
manuscript, and is reviewed in detail below, other bone
marrow disorders are mentioned in conjunction with AA, and
therefore deserve explanation.

Paroxysmal Nocturnal Hemoglobinuria (PNH)
PNH is a clonal stem cell disorder characterized by
cells deficient in glycosylphosphatidylinositol
anchored proteins
2000).

(GPI)-

(Dunn, et al., 1999; Socie, et a l .,

The traditional phenotypic marker of dark-colored

urine occurs in about half of the patients diagnosed with
PNH, and is caused by intravascular hemolysis.

Hemolysis

occurs due to an increase in compliment (immune-mediated
cell lysis) as a direct result of the deficiency in GPIanchored proteins

(Dunn, et al., 1999; Lee,

1993) .

This

deficiency is caused by a somatic mutation in the PIG-A
gene located on the X chromosome (Dunn et al., 1999; Socie,
et al., 2000).
There are three types of PNH cells, type I, type II and
type III, all of which show various sensitivity levels to
complement.
symptoms

Patients with PNH may present with AA-like

(pancytopenia with hypoplastic marrow)

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

or MDS-like

9

symptoms

(pancytopenia with cellular marrow), and

cytogenetic analyses have not provided any diagnostic
chromosomal patterns.

PNH is associated with a high rate

of thromboses, which may be fatal, and renal abnormalities
(mainly due to hepatic thromboses) .

Other than bone marrow

transplantation, which is rarely used to treat patients
with PNH, there is no definitive treatment regimen.
Complete remission is only achieved in a small number of
patients

(Lee, 1993).

Recent reports show that approximately 22-23% of
patients with A A or MDS also suffer from PNH
1999).

(Dunn, et al.,

Originally, it was thought that PNH was a late

complication of A A and MDS, however more recent data show
that cells deficient in GPI-anchored proteins
flow cytometry)
A A or MDS

(detected by

are present at the time of diagnosis with

(Colby et a l ., 1996; Dunn, et a l ., 1999; Socie,

et al., 2000; Tisdale, et al., 2000; Young,

2000).

Cells

deficient in GPI-anchored proteins were not detected in
patients treated with antithymocyte globulin
reasons other than A A or MDS

(Dunn, et al.,

(ATG) for
1999).

This

suggests that there is no correlation between ATG therapy
and the presence of cells lacking GPI-anchored proteins
(Dunn, et al., 1999; Socie, et al., 2000).

However, MDS

patients who express cells without GPI-anchored proteins
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respond better to treatment with immunosuppressive therapy,
and recent experiments by Dunn et a l - showed that cells
which are deficient in GPI-anchored proteins are less
affected by an autoimmune attack (Dunn et al., 1999).

This

phenomenon may explain why the onset of PNH may be linked
with the presence of a bone marrow failure disorder (AA or
MDS) that is thought to be a result of an autoimmune
attack.

Since cells lacking GPI-anchored proteins show

resistance to attack by the immune system, they may be
preferentially selected for in the case of such an attack.

Myelodysplastic Syndromes

(MDS)

The MDS are a group of clonal disorders that can occur
de novo, or may occur following treatment for AA (secondary
MDS).

They are characterized by anemia that does not

respond to treatment (Deiss, 1993) .

Secondary MDS has a

characteristic pattern of evolution wherein hematopoiesis
is restored (at least partially)

after treatment for AA,

followed by a subsequent decline and the onset of MDS or
other disorders

(see PNH section above)

1988; Socie et al., 2000).

(De Planque et al.,

MDS is associated with an older

age group, and is slightly more common in males
al., 2000; Deiss,

1993).

(Barrett et

There are five categories of MDS

as defined by the French, American, and British (FAB)
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group: refractory anemia (RA) , refractory anemia with
ringed sideroblasts
blasts

(RARS), refractory anemia with excess

(RAEB), refractory anemia with excess blasts in

transformation (RAEB-t) , and chronic myelomonocytic
leukemia (CMML)

(Deiss, 1993) .

Of these subsets, patients

diagnosed with RAEB or RAEB-t are more likely to undergo
leukemic transformation.

Unfortunately, classification is

based on phenotypic markers alone, and the presentation of
MDS can often be misdiagnosed as AA and vice versa

(Barrett

et al., 2000; Dunn et al., 1999; Socie et al., 2000) .

MDS

often presents clinically with one or more cytopenias
(anemia, pancytopenia, thrombocytopenia, or neutropenia)
present at the time of diagnosis
Deiss, 1993) .

(Barrett et a l ., 2000;

In addition, cytogenetic abnormalities are

commonly found at diagnosis, including 5q-, monosomy 7 and
trisomy 8.

A complex karyotype, or the presence of

monosomy 7 is considered to be a poor prognosis
al., 2000; Deiss, 1993; Socie et a l ., 2000) .

(Barrett et

It is

estimated that 10-25% of patients with MDS will progress to
acute nonlymphocytic leukemia

(ANLL).

The development of

MDS may be due to immunosuppressive therapy for a prior
malignancy (therapy-related MDS
Socie et al., 2000).

(t-MDS)) (Deiss,

1993;

In t-MDS, a greater percentage of

patients have complex cytogenetics, do not respond well to
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treatment, and a larger percentage undergo transformation
to ANLL

(Deiss, 1993) .

M an y patients are asymptomatic, and chemotherapy is
usually unsuccessful.

It is hard to evaluate the

effectiveness of various treatment regimens due to the lack
of large randomized trials with patients of the same
disease category (de novo versus secondary MDS,

etc.).

Remission is attained in approximately 50% of patients with
MDS, however relapse is very common and occurs rapidly.
Bone marrow transplant is an available option for some
patients with an HLA-matched donor, but as with all bone
marrow transplants, complications such as graft versus host
disease

(GVHD) may occur

(Deiss,

1993).

Telomere shortening has been associated with progression
to ANLL,

an increase in cytogenetic abnormalities and a

poor prognosis

(Rosenfeld and List, 2000).

Since telomeres

are responsible for genomic stability, it is possible that
the shortening of the telomeres, due to an increase in cell
divisions

(when the bone marrow is under stress)

complicated by advanced age

(Jordan and Van Zant,

and
1998),

may contribute to an increase in genomic instability and
neoplastic progression

(Marsh, 2000; Rosenfeld and List,

2 0 0 0 ).
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Collectively, the standing hypothesis regarding the
evolution of A A to MDS is as follows: 1) initial injury to
a progenitor cell occurs, possibly due to toxin exposure,
2) increased apoptosis of marrow cells

(onset of AA) , 3)

enhancement of telomere shortening resulting in genomic
instability (development of early MDS), 4) a second insult
to the cells, perhaps due to inactivation of a tumor
suppressor gene, and lastly 5) progression to advanced MDS
and ANLL

(Barrett, et al., 2000; Rosenfeld and List, 2000).

Acute Nonlymphocytic Leukemia (ANLL)
ANLL is often referred to as acute myeloid leukemia
(AML) ; however, ANLL is the more precise term and will
therefore be used in this manuscript.

ANLL is the

culmination of disease progression that can start with the
development A A followed by evolution to MDS and ending in
ANLL.

Environmental toxins, such as benzene, which

contribute to the onset of A A and MDS also contribute to
the onset of ANLL.

In addition, ANLL may arise after

chemotherapy, which damages the DNA.

Chromosomal

instability has been implicated in the development of ANLL,
and cytogenetic abnormalities are common in most patients
with ANLL

(Greer et a l ., 1999; Greer and Kinney,
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ANLL is a clonal disorder that often presents with
various cytopenias

(neutropenia, thrombocytopenia) and the

presence of blast cells
marrow.

(immature cells)

in the bone

Like MDS, the classification system for ANLL is

poor and is based on phenotypic markers.

ANLL has seven

subcategories as defined by the FAB system: Ml, M2 and M3
ANLL are mainly granulocytic, M4 ANLL shows >20% of the
cells having monocytic origin, M5 ANLL shows >80% of the
cells with a monocytic origin, M6 ANLL involves erythroid
differentiation, and M7 ANLL is megakaryocytic (Greer et
al., 1999; Greer and Kinney, 1993).
ANLL M2, M3 and M4 are associated with a good prognosis,
and ANLL M5, M6 and M7 are associated with a poorer
prognosis.

Certain cytogenetic abnormalities are commonly

seen in association with a particular subtype, such as
t(8;21) with ANLL M2 and t(15;17) with ANLL M3.

These

translocations often involve known oncogenes and could
result in their activation or the suppression of a tumor
suppressor gene.

Secondary ANLL is often associated with

monosomy 7 or 5q-, which are considered to be indicators of
a poor prognosis
1993) .

(Greer et al., 1999; Greer and Kinney,

It is of interest to note that genes for five major

cytokines are located in the 5q region (Deiss, 1993).
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As with other neoplasms, therapy involves chemotherapy or
bone marrow transplantation.

Chemotherapy involves a high

dose of induction therapy, usually cytosine arabinoside
combined with an anthracycline,
therapy.

followed by post-remission

The cure rate using chemotherapy alone is between

10-30%, while the cure rate with bone marrow
transplantation is 45-65%.

Patients with preceding MDS

often have lower response rates to chemotherapy, and
involvement of the central nervous system indicates a poor
prognosis.

Unfortunately, 40-80% of all patients will

relapse, and 10-20% of patients with ANLL do not respond to
any treatment

(Greer et al., 1999; Greer and Kinney,

Aplastic Anemia

1993).

(AA)

Background
A A is a bone marrow failure disorder that can progress to
pre-leukemic conditions
et al., 200.0) .

(MDS, etc.)

and leukemia (Barrett

A A is characterized by the lack of

precursor cell components for most cell types
Young, 1999).

(Marsh, 2000;

Essentially, bone marrow production ceases;

there is a reduction in red marrow

(hematopoiesis) and an

increase in yellow marrow (inactive fat cells)
1995; Young, 1999; Young, 2000)
is referred to as pancytopenia

(Figure 2).

(Peterson,

This condition

(Barrett et al., 2000; Lee,
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Figure 2. Hematopoiesis
(A) Normal bone marrow showing correct ratio between red
and yellow marrow components. Photograph taken from
http ://www.vet .purdue.edu/vpb/clinpath/vpb555/lectlhematopoiesis/
(B) Bone marrow failure showing a decrease in red marrow
and an increase in yellow marrow (Young, 1999)
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1999; On-line Medical Dictionary, 2001; Williams, 1993;
Young, 2000).

There are many different pathways that lead

to the development of AA, causing difficulty in proper
diagnosis and treatment for A A patients

(Guinan, 1997).

AA

can occur from exposure to toxic chemicals such as benzene
(via inhalation) Colby et al., 1996; Lee, 1999; Marsh and
Geary, 1991; Young,

1999).

Benzene can bind to DNA and

RNA, creating adducts, which can degrade and contribute to
DNA breakage

(Shackelford et al., 1999).

Radiation has

also been linked to the development of A A through nuclear
accidents or accidental exposures

(Colby et al., 1996;

Guinan,

1997; Lee,

1999; Marsh and Geary,

1991; Young,

2000).

In addition, there are a wide variety of drugs that

can induce AA, such as chloramphenicol (Colby et al., 1996;
Guinan, 1997; Lee,

1999; Young, 1999; Young, 2000).

Since

there are no firm associations between drug dosages and the
amount of time a drug was administered, it is hard to
determine which drugs have a detrimental effect
1999).

(Lee,

Recently, A A has been associated with hepatitis

patients,

although a specific connection remains

unidentified (Guinan, 1997; Lee, 1999; Young, 2000).

AA

m ay also be of familial origin, as in the case of Fanconi's
anemia (FA) , an autosomal recessive disorder characterized
by various abnormalities of the skeletal and urogenital
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systems, hyperpigmentation, and pancytopemia

(Marsh and

Geary, 1991; Russo and Zwerdling, 1992; ;Smith and Cox,
1999; Thurston et a l ., 1999) .

However, 'the vast majority

of A A cases are idiopathic (due to u n kn o nm causes)

(Colby

et al., 1996; Lee, 1999; Online Medical Dictionary, 2001;
Peterson, 1995; Storb, 1997; Young, 2000 ) .
Patients with AA present with one or imore of the
following clinical characteristics: a
blood cells

Iotw

number of red

(anemia) , a low number of wh.ite blood cells

(leukopenia) and/or a low number of plat>elets
(thrombocytopenia)
2001) .

(Lee, 1999; Online Me»dical Dictionary,

Due to the wide variety of abnormalities with

symptoms and clinical findings similar t*o A A (PNH, M D S ) ,
diagnosis is often difficult

(Lee, 1999;

Young,

1999).

Occasionally, cytogenetic abnormalities ^are present, which
indicates a poor prognosis and a greater

potential for

disease progression to MDS or ANLL (Barr*ett et a l ., 2000;
Kaito et al., 1998; La Starza et al., 19:98; Ohara et a l .,
1997; Thurston et a l ., 1999) .
The majority of patients with AA have
analysis

(Barrett et al., 2000).

aplastic anemia (SAA)

a normal karyotype

In patiients with severe

(criteria established by the

International Aplastic Anemia Study Groujp) , cytogenetic
abnormalities usually include monosomy 7., trisomy 8 and/or
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trisomy 21

(Barrett et al., 2000; Colby, et al., 1996; La

Starza et al.,

1998; Ohara et al., 1997; Russo and

Zwerdling, 1992; Thurston et al., 1999) .

As with MDS, the

presence of monosomy 7 is considered a poor prognosis
(Thurston et a l ., 1999).

The degree of severity of AA is

diagnosed using the standards set forth by the
International Agranulocytosis and Aplastic Anemia Study
Group

(Colby et al.,

1996; Kaito et al.,

1998; Lee, 1999).

It is estimated that 10% of patients with AA will develop
PNH and 5-15% of patients with A A will progress to MDS or
ANLL (Kaito et al., 1998; Ohara et al., 1997; Socie et al.,
2000; Tisdale,

et al., 2000; Young,

1999).

In those

patients who progress to MDS, chromosomal abnormalities are
frequently seen, and assist in the diagnosis of MDS
(Barrett et a l ., 2000; Kaito et a l ., 1998; Ohara et a l .,
1997; Socie et al., 1993; Young,

1999). Recent studies have

linked the development of cytogenetic abnormalities such as
monosomy 7 and trisomy 21 to previous treatment with G-CSF
(Kaito et a l ., 1998; Ohara et al., 1997; Young, 1999).
This link has been noted in both children
1997) and adults

(Kaito et al., 1998) .

(Ohara et a l .,

G-CSF stimulates

myelopoiesis and can assist in combating infection
following immunosuppressive therapy
Rosenfeld, 2000; Marsh, 2000; Sachs,

(Frickhofen and
1996; Young, 1999).

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

20

However,

it is important that treatment with any cytokine

be appropriately timed to ensure the destruction of all
malignant cells

(Sachs, 1996).

It is theoretically

possible that the treatment of patients,

in the Ohara and

Kaito studies, with both immunosuppressive therapy and GCSF simultaneously may have resulted in protection of
malignant cells from apoptosis followed by an expansion of
the malignant cells.

The common factor in all patients who

exhibited complications, such as MDS or PNH, was treatment
with G-CSF for over one year (Kaito et a l ., 1998; Marsh,
2 0 0 0 ).

A recent study, of a patient with FA, using fluorescence
in situ hybridization (FISH) , showed a higher percentage of
cells with monosomy 7 than was recorded using conventional
metaphase karyotype analysis.

In addition, retrospective

analysis indicated an increase in monosomy 7 levels over
time

(Thurston, et a l ., 1999).

This and other studies show

that FISH can detect chromosome abnormalities that are
undetected by a karyotype analysis

(Thurston et al., 1999;

Socie et al., 2000; Young, 1999; Young, 2000).

Such

analysis is particularly useful in patients with AA, since
routine karyotype analysis can be difficult because there
is a lack of dividing cells

(Barrett et a l ., 2000; De
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Planque et al., 1988; Socie et al., 2000; Tichelli et al.,
1988) .
Numerous recent reports support the hypothesis that
acquired A A is an autoimmune disorder that is caused by
attack on the hematopoietic system by lymphocytes
(Colby et al., 1996; Tisdale,
Young, 2000).
signals

(T-cells)

et al., 2000; Young, 1999;

Lymphocytes are recruited via cytokine

(INF, IL2 and TNF), which leads to the activation

of apoptosis via the Fas/Fas ligand pathway (Tisdale, et
al., 2000; Young, 1999).

INF-y and TNF-a levels are

increased in patients with SAA, which can cause an increase
in Fas-mediated apoptosis
2000).

(Colby et a l ., 1996; Young,

This autoimmune destruction may select for cells

which are unaffected by autoimmune attacks such as PNH
clones

(see previous PNH section) or cells that are

resistant to apoptosis

(MDS), causing clonal expansion of

those cells and the manifestation of the clinical disorders
(Young, 1999; Young, 2000)

(Figure 3).
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Antigenic Stimulus

immune Response

Activated
T Ceils .

Neoantigen

Apoptotc
Ceils

Quiescent T Ceil
Virus

Autoimmune Destruction

Figure 3.

Clonal Escape

Hypothetical Pathway of Autoimmune Destruction

Stem cell insult occurs from drug exposure etc. (a viral
infection is shown here), which causes a change in the
production of the cell proteins and cell surface markers.
T cells are activated by a normal immune response to
"foreign" cells and apoptosis occurs.
Emergence of
resistant clones results in clinical manifestations (Young,
1999) .

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

23

Epidemiology
A A is primarily a disease of the young, with an average
age of twenty-five

(Young, 2000).

In the United States and

Europe, the incidence of A A is approximately 2 per million
(Storb, 1997; Young,

1999; Young, 2000), while rates in the

Far East are as high as 11 per million (Storb, 1997).

AA

is more common in developing nations perhaps owing to the
lack of industrial standards and a higher rate of exposure
to toxins such as benzene
common in males

(Lee, 1999).

(Barrett et al., 2000).

study by Kaito et al.

AA is slightly more
However,

in a

(1998), looking at the rate of

transformation from A A to MDS, no statistical correlation
was found with respect to the age of the patient, the sex
of the patient, or the severity of the disease.

Treatment
Bone marrow transplant is the treatment of choice, except
in cases where the age of the patient or lack of a suitable
donor prohibits transplantation (Colby et a l ., 1996;
Guinan,

1997; Lee,

1999; Young 2000).

Survival rates of up

to 90% are achieved in young patients who undergo bone
marrow transplantation prior to the increase of GVHD, which
is found in patients over 30 years of age (Young, 2000).
Whole body irradiation has decreased the rate of GVHD;
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however, the consequences of total irradiation can lead to
future complications or death (Lee, 1999).

Patients with

no history of blood transfusions prior to bone marrow
transplantation have a better chance of survival and
remission (Colby et al., 1996; Guinan,

1997; Lee,

1999).

Transfusions can increase the chance of graft rejection by
causing an increased sensitivity to histocompatability
antigens

(Colby et al., 1996).

The overall survival rate

of patients undergoing bone marrow transplantation has
continued to improve due to advances in technology (Guinan
1997; Lee, 1999) .
In cases where bone marrow transplant is not an option,
immunosuppressive therapy is the second choice
and Rosenfeld, 2000; Guinan,
Young, 2000).

1997; Lee, 1999; Young,

1999;

Treatment usually consists of ATG alone or

in combination with cylosporin A (CsA)
Guinan,

(Frickhofen

(Colby et al., 1996

1997; Lee, 1999; Young, 1999; Young, 2000) .

ATG

works by inhibiting T cell mediated immune response,
although the exact mechanism is unknown (Colby et al.,
1996; Frickhofen and Rosenfeld, 2000; Young, 2000) .

CsA

inhibits the transcription of several cytokines, blocking
an immune response

(Frickhofen and Rosenfeld, 2000).

The

rate of survival in patients who respond to
immunosuppressive therapy can reach as high as 90%
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2000).

The responsiveness of a patient is associated with

the severity of the disease
1997; Lee, 1999).

(Colby, et al-,

1996; Guinan,

G-CSF has been administered to some

patients with AA, however treatment with G-CSF alone cannot
induce remission (Young, 2000).

G-CSF stimulates the

myelopoiesis, and can aid in the effectiveness of other
immunosuppressive drugs
Guinan,

(Frickhofen and Rosenfeld, 2000;

1997; Marsh, 2000; Young, 1999; Young, 2000).

Unfortunately, immunosuppressive treatment has been
associated with an increased risk of developing a
hematological disorder,

such as PNH, MDS or ANLL

(Frickhofen and Rosenfeld,
Tisdale,

2000; Lee, 1999; Marsh, 2000;

et al., 2000; Young, 2000).

Research is ongoing

to establish a better therapy regimen that increases
overall survival and remission rates while decreasing the
risk of developing future complications

(Guinan, 1997; Lee,

1999).
Alternate therapies to ATG and CsA are being investigated
such as cyclophosphamide,

a potent immunosuppressive drug

(Frickhofen and Rosenfeld,
Young,

1999; Young, 200 0).

2000; Tisdale, et al., 2000;
Preliminary data shows that

patients treated with cyclophosphamide do not develop
clonal disorders

(PNH or MDS)

et al., 2000; Young,

and do not relapse

1999).
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In addition to immunosuppressive therapy, supportive
care, such as regular blood transfusions,

is part of the

treatment regimen (Lee, 1999; Young, 2000).

However,

caution should be used when the patient is eligible for a
bone marrow transplant, since patients who have not had any
prior blood transfusions have a greater successful response
rate to bone marrow transplantation (Lee, 1999).

Another

key to successful treatment that is often overlooked, is
prevention of infection, which can only compound problems
within an already reduced immune system (Lee, 1999).

CELL CYCLE

General Overview
By definition, the cell cycle is "the sequence of events
between mitotic divisions"
2001) .

(Online Medical Dictionary,

The end result from one round of cell division is

two genetically identical daughter cells
Walker,

1999).

(Johnson and

The cell cycle includes interphase

(comprised of Gl, S and G2) and mitosis

(Figure 4) .

Cells

that are quiescent are in GO, a non-dividing cell resting
state

(Jacks and Weinberg, 1998; Johnson and Walker, 1999;

Shackelford et al.,

1999).
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The Cell Cycle

Photograph taken from
h t t p ://www.geocities.com/CollegePark/Lab/1580/cycle.html
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During Gl, the cell synthesizes RNA and proteins in
preparation for DNA replication (Hagan et al.,
Johnson and Walker,

1999;

1999) . G1 is the longest stage (in

animals), comprising nearly half of the total cell cycle
time

(Shackelford et al.,

1999).

During the S phase, the

DNA is replicated, and upon completion, the cell now
contains two copies

of the same DNA (Hagan et al.,

1999;

Johnson and Walker,

1999). S phase comprises almost one

quarter of the entire cell cycle time (Shackelford et al.,
1999).

During G2, the cell prepares to enter mitosis

(Hagan et al., 1999; Johnson and Walker, 1999).

G2 phase

comprises less than one quarter of the total cell cycle
time.

G2 is followed by mitosis, which is the shortest

part of the cell cycle.
hours

The cell cycle repeats every 18-24

(Shackelford et al.,

1999).

Mitosis is broken down into four substages: prophase,
metaphase, anaphase and telophase.

During prophase, the

mitotic spindle begins to form in the cytoplasm.
chromatin condenses,

The

forming the X-shaped chromosomes, and

the centrosomes, comprised of two centrioles, begin to move
apart.

In preparation for metaphase, the nuclear envelope

disintegrates, and the centrosomes localize to the spindle
poles on opposite sides of the cell.
comprised of microtubules,

The spindle fibers,

attach to the kinetochores,
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which are located in. the centromeric region of each
chromosome

(Willard,

2000) .

In metaphase,

the chromosomes

attach to the spindle apparatus as they begin to align
along the metaphase plate in between the two spindle poles.
During anaphase, the sister chromatids divide and move
toward opposite poles with help from the spindle apparatus
attached to the kinetochore region.
of mitosis,

telophase,

During the final phase

the nuclear envelopes begin to

reform, with one envelope surrounding each set of
chromosomes.

The chromatin begins to uncoil, and the

cytoplasm divides

(cytokinesis)

(Campbell,

1993).

Mitotic Cell Cycle Checkpoint Mechanisms
Many cell cycle controls

(checkpoints)

are built into the

cell cycle to ensure correct cell division
Walker, 1999; Shackelford et al., 1999).

(Johnson and
Cell cycle

checkpoints are mediated by the activity of cyclin/cdk
(cyclin-dependent kinase) complexes
Shackelford et al.,

1999).

two main checkpoints.

(Hagan et al.,

During interphase,

al., 1999)

there are

The first checkpoint is a

restriction point located prior to the S phase
and Kastan,

1999;

1994; Johnson and Walker,
(Figure 4 and Figure 5).

(Hartwell

1999; Shackelford et
Here, the cell must

decide whether to continue in the cell cycle or abort and
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Cyclin/cdk Complexes Within the Cell Cycle

Pictorial representation of the Cyclin/cdk protein
complexes and their locations within the cell cycle control
(Shackelford et al., 1999).
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enter the GO quiescent stage

(Johnson and Walker,

1999).

Once the cell has decided to continue with the cell cycle,
there is no turning back

(Johnson and Walker,

Shackelford et al., 1999).

1999;

The G1 checkpoint ensures that

damaged DNA is not replicated (Hartwell and Kastan,

1994) .

The second checkpoint occurs in late G2, prior to entering
mitosis

(Johnson and Walker,

1999; Shackelford et al.,

1999).

This checkpoint is controlled by the levels of

maturation (or M phase) promoting factor (MPF), and ensures
that DNA replication is complete prior to the initiation of
mitosis

(Hartwell and Kastan,

1994; Shackelford et al.,

1999).
D-type cyclins induce the division of GO cells.

The

levels of D-type cyclins remain constant throughout the
cell cycle (Johnson and Walker,

1999).

D-type cyclin

kinases phosphorylate the retinoblastoma tumor suppressor
protein (Rb), which is involved in the restriction point
during G1
Walker,

(Figure 5)

(Bartek et a l ., 1999; Johnson and

1999; Shackelford et al., 1999).

phosphorylation,

After

the Rb protein dissociates from E2F, a

transcription factor that regulates the expression of
cyclin E.

The formation of a cyclin E/cdk2 complex is

required for the transition into S phase

(Figure 5).

Cyclin A negatively regulates E2F (Johnson and Walker,
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1999; Shackelford et al., 1999). Entry into mitosis is
controlled by MPF, which is controlled by the level of
cyclin B (Hagan et al., 1999; Shackelford et al., 1999).
Cyclin B binds to p34cdc2 (cell division cycle 2), a cdk that
is part of the MPF

(Figure 5)

(Shackelford et al., 1999).

Upon binding to cyclin B, and after phosphorylation, p3 4cdc2
becomes active.

When p34cdc2 is active,

it will activate the

MPF, phosphorylate many cell cycle components,
the formation of the mitotic spindle
Shackelford et al.,

1999).

and initiate

(Hagan et al., 1999;

During mitosis,

cyclins A, B1

and B2 associate with cdkl, and are responsible for
phosphorylation of a wide variety of targets including
components of the mitotic spindle
1999; Shackelford et a l ., 1999).

(Johnson and Walker,
Mitosis is completed when

the destruction of cyclin B inhibits MPF function (Hagan et
al., 1999).

Once the cell has completed mitosis, the

process begins anew with cyclin building up until it
reaches the threshold level required to initiate cell
division (Hagan et a l ., 1999; Johnson and Walker,
Cyclin-dependent kinase inhibitors
cyclin/cdk complexes

1999).

(OKI) regulate the

(Johnson and Walker,

1999) .

One

member of this family is p21, which is activated by p53,
and (when active)
cell cycle.

is responsible for the inhibition of the

Activation of p21 halts DNA replication to

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

33

allow for repair of damaged DNA (Johnson and Walker,
Shackelford et al., 1999).

1999;

Therefore, certain cancers that

have altered p53 function may be unable to activate p21,
which would allow damaged DNA to undergo replication.
Mutations in p53 are common in cancer, which leads to an
increase in genomic instability manifested by a high level
of chromosomal abnormalities

(Johnson and Walker, 1999) .

Another CKI, pl6, is known to inhibit Rb phosphorylation
(Johnson and Walker, 1999; Shackelford et a l ., 1999).

When

Rb phosphorylation is inhibited, E2F is not activated and
the cell cannot undergo DNA replication.
During metaphase, the chromosomes align along the
metaphase plate prior to their separation during anaphase.
Separation of chromosomes is assisted by microtubules in
the mitotic spindle that are attached to one of the two
microtubule organizing centers
spindle poles.

(MTOCs) located at the

Movement of the chromosomes is accomplished

by microtubule motor proteins

(Hagan et al., 1999) .

The

mitotic spindle checkpoint ensures that all chromosomes are
aligned properly and attached to the spindle apparatus
before division occurs

(Davenport et al., 1999; Elledge,

1998; Hwang et al., 1998; Imai et al., 1999; Nicklas,
Paulovich et al., 1997).

1997;

The mitotic spindle checkpoint is

comprised of genes from the MAD (mitotic arrest deficient)
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and BUB (budding uninhibited by benzimidazole)

families and

is discussed in further detail below (Shackelford et al.,
1999).

A defect in the mitotic spindle checkpoint would

allow premature anaphase and may lead to uneven chromosome
division.

BUB and M A D Gene Families

In the yeast Saccharomyces cerevisiae, there are seven
genes identified (to date) which are required for the
spindle assembly checkpoint.

These include BUB genes 2, 2

and 3, MAD genes I, 2 and 3, and MPS1,

(monopolar spindle

1) a protein kinase (Basu, et al., 1999; Bernard et a l .,
1998; Hardwick, et al., 1996; Jin et al., 1998; Pangilinan
et al., 1997) .
MAD2 and MAD3

Mammalian homologues of BUB1, BUB3, MAD1,
(which is occasionally referred to as BUBR1,

due to similarities to both the BUB and MAD gene families)
localize during prometaphase to the kinetochore region of
chromosomes that are not attached to the spindle apparatus,
and disappear once stable attachment is achieved during
metaphase

(Elledge, 1998; Fraschini et al., 1999; Hardwick

et al., 2000; Li and Benezra,

1996; Li, 1999).

However,

BUB2 localizes to the spindle poles, indicating a
potentially different function from BUB1, BUB3, MAD1 and
MAD2

(Fraschini et al., 1999; Hardwick et al., 2000; Li,
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1999) .

Many hypothesize that BUB1, BUB3 and MAD1-3

proteins all form a complex that targets unattached
kinetochores, comprising the mitotic spindle checkpoint
(Fraschini et al., 1999; Li, 1999; Seeley et a l ., 1999).
It is also hypothesized that BUB2 assists in the regulation
of cytokinesis

(Fraschini et al., 1999; Li,

1999).

Evidence supporting this theory is found in fission yeast
where cdcl6, the fission yeast homologue of BUB2,
negatively regulates cytokinesis, and is localized to the
spindle poles

(Fraschini et al., 1999; Li,

1999).

The

kinetochore-binding domain CENP-E has also been implicated
in the mitotic spindle checkpoint (Chan et a l ., 1998).
Like the other checkpoint proteins, CENP-E localizes to the
kinetochore

(Chan et al., 1998).

CENP-E is a motor-kinase

and is thought to contribute in the shortening of the
spindle apparatus during metaphase

(Chan et al., 1998) .

There is evidence that BUB1, BUB3 and MAD1-3 proteins all
interact

(Figure 6).

BUB1 undergoes autophosphorylation

and also phosphorylates BUB3 (Farr and Hoyt,
Hardwick,

1998; Martinez-Exposito et al.,

al., 1994; Taylor and McKeon, 1997).

1998;

1999; Roberts et

In addition,

the

binding of BUB3 to BUB1 is necessary for kinetochore
localization of BUB1

(Fraschini et al., 1999; Seeley et

al., 1999; Taylor et a l ., 1998).

MAD3

(BUBR1) binds to
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CDC20

(APC activator)

BUB1
inhibits

(El

BUB3

MAD3/
BUBR1

MAD2

MAD1

Auto

MAD1

BUB1

BUB3
BUB I

BUB3

MPS1

Figure 6. Hypothesized Interaction of the BUB/MAD
Proteins, and Their Possible Role in the Regulation of the
Mitotic Spindle Checkpoint.
BUB1 binds to BUB3, which is necessary for kinetochore
localization of BUB1.
BUB3 is phosphorylated by BUB1 and
BUB1 is autophosphorylated.
The BUB1/BUB3 complex binds to
MAD1, and MAD1 is phosphorylated by MPS1.
From there, it
is hypothesized that MAD2 and MAD3 (BUBR1) are added to the
complex.
By an unknown mechanism, the newly formed complex
inhibits CDC20 which prevents activation of the APC.
By
inhibiting the activation of the APC, anaphase is blocked.
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BUB3,

(Hardwick et al-, 2000; Taylor et al.,

binds to BUB1 (Seeley et al., 1999).

1998)

and MAD1

MAD 1-3 interact with

each other and with the anaphase promoting complex

(AJ?C) in

yeast, and MAD2 is able to inactivate CDC20 and stabilize
Pdsl

(in S. cerevisiae)

and cyclin B.

This blocks the

onset of anaphase by preventing the destruction of Pdsl and
cyclin B (Elledge, 1998; Hardwick et al., 2000; Hwang et
al., 1998; Li and Benezra,

1996; Taylor et al.,

1998).

MAD1 binds to MAD2, and MAD1 is phosphorylated by MPS1
(Bernard et al., 1998; Farr and Hoyt, 1998; Fraschini et
al., 1999; Taylor and McKeon,

1997; Taylor et a l ., 1998).

CENP-E has been shown to colocalize and bind to MAD3
(BUBR1) at the kinetochore region (Chan et a l ., 1998; Chan
et a l ., 1999).

hBUBl

Characteristics
The human BUB1 protein is a 1,021 amino acid (aa), 188kDa protein which contains three main functional domains:
CD1, which is highly conserved and directs kinetochore
localization, NLS, a nuclear localization signal sequence
and CD2, a highly conserved carboxy-terminal serinethreonine-like protein kinase domain (Cahill et al., 1999;
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Pangilinan et al., 1997; Roberts et a l ., 1994).

Both

kinetochore localization (the BUB1 protein must be near the
kinetochore region

to facilitate in the binding of the

mitotic spindle to

the kinetochore)

and nuclear

localization (the BUB1 protein must be within the nucleus
of the cell to be able to localize to the kinetochore) of
hBUBl are essential to the function of hBUBl.

hBUBl is a

protein kinase with 25 exons located on chromosome 2ql2-ql4
(Cahill et al., 1999; Pangilinan et al.,
al., 1994) .

Exons 2-5 (codons 21-152)

1997; Roberts et

encode for the CD1

region, while exons 8 and 9 (codons 207-319)
NLS region,

encode for the

and exons 20-25 (codons 732-1043)

the CD2 region.

A

CD1 and CD2 in the

encode for

hBUB3 binding site islocated between
presumptive NLS area

1998; Cahill et al., 1999).

(Cahill et al,

Cahill et al. found that two

of 19 colorectal cancer cell lines had mutations within
hBUBl, and also showed high levels of aneuploidy (Cahill et
al., 1998).
BUB1 homologues have also been found in a variety of
organisms,

including mice

Drosophila

(Basu et al.,

(Taylor and McKeon,

1997),

1999), fission yeast

Schizosaccharomyces pomhe (Bernard et a l ., 1998)

and

Aspergillus nidulans

Bernard et

(Efimov and Morris,

1998).

a l . showed that in S. pomhe, BUB1 was also localized to the
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kinetochore region upon activation of the spindle
checkpoint.

In addition, loss of the BUB1 gene in S. pombe

instigated chromosomal segregation defects, from failure of
sister chromatid segregation, producing a higher aneuploidy
rate, and an increase in lagging chromosomes in late
anaphase (Bernard et al., 1998).

Taylor and McKeon showed

that when the function of the murine homologue of BUB1 is
abrogated (a suppressed mitotic spindle checkpoint), cells
successfully avoid apoptosis and continue in the cell cycle
(Taylor and McKeon,

1997).

Basu et al. found that in

Drosophila, severe mutations of BUB1

(missgregation and

fragmentation) were responsible for elevated levels of
chromosome abnormalities, and ultimately death of the
Drosophila larvae

(Basu et al., 1999).

Taylor and McKeon's findings

In contrast to

(above, Taylor and McKeon,

1997), severe mutations of BUB1 in Drosophila induced a
higher apoptotic state (Basu et al., 1999).

The study of

BUB1 in Drosophila is the first study to assess BUB1 in a
multicellular organism (Basu et al., 1999).

GENOMIC INSTABILITY AND CANCER

The hallmark of cancer is an uncontrolled cell cycle
(Bartek et al., 1999; Hartwell and Kastan,

1994; Johnson
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and Walker,

1999).

The accumulation of mutations may lead

to cancer (Imai et al., 1999: Ohshima et a l ., 2000; OrrWeaver and Weinberg, 1998).

Many hypothesize that genetic

instability leads to an increase in the mutation rate and
the onset of cancer (Boland and Ricciardiello, 1999; Cahill
et al., 1998; Hartwell and Kastan,

1994; Imai et a l ., 1999;

Jaffrey et al., 2000; Lengauer et al., 1997; Myrie et al.,
2000; Ohshima et al., 2000).

There are two forms of

genetic instability: chromosomal instability (CIN) and
microsatellite instability (MIN)

(Cahill et al., 1999; Imai

et al., 1999; Jaffrey et a l ., 2000) .

Chromosomal Instability
CIN is characterized by malsegregation of chromosomes and
presents as aneuploidy at the chromosomal level (Bernard et
al., 1998; Cahill et a l ., 1998; Cahill et al., 1999; Imai
et al, 1999; Jaffrey et a l ., 2000; Lengauer, et a l ., 1997;
Myrie et a l ., 2000; Orr-Weaver and Weinberg,

1998).

Aneuploidy and other chromosomal aberrations are frequently
associated with a variety of cancers and tumors (Boland and
Ricciardiello,
Kastan,

1999; Davenport et al., 1999; Hartwell and

1994; Imai et al., 1999; Lengauer et al., 1997;

Myrie et al., 2000; Yamaguchi et al., 1999).
Theoretically,

aneuploidy may occur as a direct result of
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an aberrant mitotic spindle checkpoint (Bernard et al.,
1998; Cahill et al.,

1998; Cahill et al., 1999; Jaffrey et

al., 2000; Ohshima et al., 2000; Orr-Weaver and Weinberg,
1998).

Cells that proceed to anaphase before all

chromosomes are aligned along the metaphase plate may
result in a gain or loss of chromosomes.

Monosomy 7 and

other abnormalities have been observed in patients with AA,
MDS and ANLL

(Barrett et a l ., 2000; De Planque et a l .,

1988; Kaito et al.,

1998; Ohara et a l ., 1997; Socie et al .,

2000), and monosomy 7 is associated with a poor prognosis
(Greer, et al., 1999).

Microsatellite Instability
MIN is characterized by mutations in mismatch repair
genes, and results in mutations at the nucleotide level
(Boland and Ricciardiello,

1999; Cahill et a l ., 1998;

Cahill et al., 1999; Lengauer et al., 1997; Orr-Weaver and
Weinberg,

1998).

Tumors with MIN usually contain the

correct number of chromosomes and do not exhibit aneuploidy
(Orr-Weaver and Weinberg,

1998).

However, nucleotide

mutations may occur in oncogenes and tumor suppressor
genes, leading to the inactivation of tumor suppressor
genes or the activation of oncogenes

(Cahill et al., 1999).
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HYPOTEHSIS AND RESEARCH AIMS

In this study,

I hypothesized that mutations or base pair

changes within the mitotic spindle checkpoint gene hBUBl
directly correlated with the presence of aneuploidy in
patients with bone marrow failure disorders.

To test this

hypothesis, two specific aims were addressed.
Recent experiments have shown that the emergence of
abnormal clones in patients with AA coincides with a
transformation to MDS
al., 2000).

(De Planque et a l ., 1988; Socie et

In addition,

as the disease progresses, more

cytogenetic abnormalities occur (Socie et a l ., 2000).
present,

At

karyotype analysis is used to evaluate the

cytogenetic makeup of a patient.

However,

in patients with

AA, this is often hard to accomplish because of the low
number of metaphase cells present (Barrett et al., 2000; De
Planque et al.,
1988).

1988; Socie et a l ., 2000; Tichelli et a l .,

Some researchers have shown that cytogenetic

analysis by FISH is more sensitive than karyotype analysis
(Thurston et al.,
Young, 2000).

1999; Socie et a l ., 2000; Young, 1999;

In addition, FISH can be performed on

patients with AA,

since the procedure is primarily

performed on interphase nuclei and does not rely on the
existance of metaphase cells.

Perhaps FISH analysis can
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detect early clonal abnormalities normally missed with,
karyotype analysis, and provide a "warning sign",
indicating a potential transformation to MDS.

Early clonal

changes have been detected by karyotype in patients prior
to transformation to MDS or ANLL
Socie et al., 2000).

(Marsh and Geary, 1991;

In addition, a Seattle study showed

that a greater percentage of A A patients with an abnormal
karyotype underwent transformation to MDS or ANLL, while
very few A A patients with a normal karyotype progressed to
MDS or ANLL (Socie et a l ., 2000) .

Marsh and Geary have

concluded that "an acquired clonal cytogenetic marker in a
patient with otherwise typical AA represents a preleukaemic state"

(Marsh and Geary, 1991).

Therefore, my

first specific aim was to compare conventional karyotype
analyses with FISH analyses in samples from patients with
AA.

Initial cytogenetic testing using FISH analysis may

complement a karyotype analysis, and could assist in a more
complete and earlier diagnosis and guide correct
preventative treatment in patients with AA.

Patients with

MDS and ANLL commonly present with either monosomy 7 or
trisomy 8, of which, monosomy 7 is considered a poor
prognosis

(Socie et al., 2000).

Therefore, FISH was

performed for chromosomes 7 and 8.
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Secondly, aneuploidy is common in many cancers, and may
be caused by a variety of things, such as structural
defects in centrosomes or the mitotic apparatus, or defects
in cell cycle control

(Bartek et al., 1999; Pihan et al.,

1998; Saunders et a l ., 2000).

Some cancerous cell lines

contained abnormal centrosomes and showed high levels of
CIN and aneuploidy that were not seen in normal cell lines
(Pihan et al., 1998).

Other cancerous cell lines were

shown to have multipolar spindles, perhaps due to a defect
in the MTOCs

(Saunders et al.,

2000).

Theoretically, aneuploidy may also be caused from an
aberrant mitotic spindle checkpoint.

When the mitotic

spindle checkpoint is viewed as a complex, one can assume
that dysfunction in any of the components may compromise
the function of the checkpoint.

hBUBl is the most

characterized of the mitotic spindle checkpoint genes, and
was mutated within two colorectal cancer cell lines
et al., 1998).

(Cahill

Therefore, as m y second specific aim, I

chose to look for the presence of mutations or base pair
changes within hBUBl in samples from patients with AA.
Since some mutations in hBUBl have a dominant negative
effect

(Cahill et al.,

1998), any mutation that alters the

function of BUB1 could potentially alter the mitotic
spindle checkpoint.

Should this be the case, one might
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predict to find a high level of aneuploidy in patients
having a mutation in the hBUBl gene.

Therefore, the same

subset of patients underwent both FISH analysis and
sequencing of the hBUBl gene functional domains shown to be
required for kinetochore and nuclear localization
NLS)

(Cahill et al.,

(CD1 and

1999; Pangilinan et a l ., 1997; Roberts

et al., 1994).
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CHAPTER XI
MATERIALS AMD M E T H O D S

PATIENT SAMPLES

The National Institutes of Health, Heart, Lung and Blood
Division in Bethesda, Maryland kindly provided patient
samples consisting of whole bone marrow.

The institutional

review board authorized the use of human samples

(IRB#

1303000246E)

SOLUTIONS

Below is a listing of solutions used in this study and
their corresponding formulas:

•

2X SSC: Combined 100ml 20X SSC, pH 7.0 with 900ml water.

•

20X SSC, pH 7.0; 3M sodium chloride,
Combined 175.3g sodium chloride
citrate

(Sigma) in 800ml water.

0.3M sodium citrate:

(Sigma) and 88.2g sodium
The pH was adjusted to

7.0 and water was added to a final volume of 1L.
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•

4X SSC/0.05% Tween 20, pH 7.0: Combined 200ml 20X SSC, pH
7.0 with 0.5ml Tween 20 (Fisher) and added water to at
final volume of 1L.

•

4X SSC/0.05% Tween 20/0.05% blocker: Combined 200ml 2:0X
SSC, pH 7.0 with 0.5ml Tween 20 and 0.5g blocker
(Boehringer Mannheim) .

Water was added to a final vo»lume

of 1L.
•

50% formamide/2X SSC, pH 7.0: Combined 50ml formamide:
(Fisher), 10ml 20X SSC, pH 7.0 and 40ml water to a fi_nal
volume of 100ml.

•

60% formamde/2X SSC/10% dextran sulfate: Combined 6nfL
formamide,

1ml 20X SSC, pH 7.0 and lg dextran sulfate: -

Water was added to a final volume of 10ml.

Solution

was

stored at -7 0°C until use.
•

70% formamide/2X SSC: Combined 70ml formamide,

10ml 2:OX

SSC, pH 7.0 and 20ml water to a final volume of 100ml..
•

DAPI, stock (lOmg/ml) : Dissolved lOmg DAPI (Sigma)
phosphate buffered saline

•

in_ 1ml

(PBS).

Ethidium Bromide, stock (lOmg/ml): Dissolved lg ethidiium
bromide

(Sigma) in 100ml water.

Solution was stored

in

the dark.
•

Fixative: Combined 75ml methanol
glacial acetic acid (Fisher)

(Fisher) and 25ml

for a final volume of 10‘0ml.
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•

Lennox broth (LB) agar plates: Combined lOg tryptone
(Difco), 5g yeast extract
lml IN sodium hydroxide

(Difco) , 5g sodium chloride,

(Fisher) and 15g agar

with water added to a final volume of 1L.

(Difco)

Autoclaved.

Cooled solution to 5 0 °C and added the following
antibiotics: lml ampicillin
(lOOmM)

(50mg/ml)

(Sigma),

(Sigma) , and lml X-gal (20mg/ml)

lml IPTG

(Sigma) .

15ml

of the solution was aliquoted into a sterile 100mm petri
dish and allowed to dry in a laminar flow hood for 30
minutes.
•

Plates were stored at 4°C until use.

LB media: Combined lOg tryptone, 5g yeast extract,

5g

sodium chloride and lml IN sodium hydroxide with water
added to a final volume of 1L.

Autoclaved.

LB media was

stored at 4°C until use.
•

Phosphate buffered saline
chloride,

(PBS), Ix, pH 7.4; 0.14M sodium

0.003M potassium chloride,

phosphate, dibasic,

0.01M sodium

0.002M potassium phosphate,

monobasic: Combined 8g sodium chloride, 0.2g potassium
chloride (Fisher),

1.44g sodium phosphate,

dibasic

(Fisher) and 0.24g potassium phosphate, monobasic
(Fisher) in 800ml water.

The pH was adjusted to 7.4 and

water was added to a final volume of 1L.

The solution

was autoclaved.
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•

Potassium chloride, 0.075M solution: Dissolved 2.8g
potassium chloride in 500ml water.

•

Tris-EDTA (TE) buffer, pH 7.4; 0.0007M Tris-Cl, 0.001M
EDTA: Combined 0.112g Tris-Cl (Sigma) and 0.372g disodium
thylenediamine tetraacetate (EDTA)

(Fisher).

Water was

added to a final volume of 500ml.

HARVEST OF BONE MARROW CELLS

The bone marrow samples were harvested upon receipt using
the following protocol: 0.075M KC1 was warmed to 37°C while
0.5ml bone marrow sample was aliquoted into a labeled 15ml
centrifuge tube.

The cells were vortexed while adding

warmed 0.075M KC1 to a total volume of 5ml, followed by a
10 minute incubation in a 37°C water bath.

While the cells

were incubating, fresh fixative was prepared (see
solutions).

The cells were centrifuged at 1000 rpm for 5

minutes, and the supernatant was discarded to just above
the white band of cells.

The cells were vortexed while 5ml

of fresh fixative was added dropwise, then the cells were
re-centrifuged at 1000 rpm for 5 minutes.

The addition of

fixative followed by centrifugation was repeated twice.
Again the cells were vortexed while 5ml of fresh fixative
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was added dropwise, and the cells were stored in fixative
at -20°C until further use.

LABELING OF FISH DNA PROBES

In this study, a pre-mixed nick translation mix by
Boehringer Mannheim was used according to the
manufacturer's protocol.

Briefly, dATP, dCTP, dGTP, dTTP,

molecular biology grade (MBG) water

(5 prime-^3 prime), and

a fluorescent label (see below) were combined to form the
"5X fluorophore-labeling mix".

Nick translation mix,

template DNA and MBG water were added to the 5X
fluorophore-labeling mix.

The sample was incubated for 90

minutes at 15°C followed by a 10-minute incubation at 65°C.
The samples were stored at -20°C until use.
Two-probe, two-color FISH was performed on chromosomes 7
and 8 simultaneously.
Biotin-16-dUTP

Chromosome 7 was labeled with

(biotin-16-2' -deoxyuridine-5'-triphosphate)

(Boehringer Mannheim)

and detected with NeutrAvidin-

fluorescein (Molecular Probes).
with DIG-ll-dUTP

Chromosome 8 was labeled

(digoxigenin-11-2'-deoxy-uridine-5'-

triphosphate)

(Boehringer Mannheim)

and detected with anti-

DIG rhodamine

(Boehringer Mannheim) .
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FLUORESCENCE I N SITU HYBRIDIZATION (FISH)

Slides were prepared as follows: the fixed cells were
centrifuged at 1000 rpm for 5 minutes, and the supernatant
was discarded.

Fresh fixative was prepared (see

solutions), and while vortexing the cells,
added until a milky color was obtained.
cleaned with ethanol
(Kimberly Clark).

(Fisher)

the fixative was

Slides were

and dried with a KimWipe

Twenty microliters of the cell

suspension was dropped onto each slide and allowed to air
dry.

The slides were stored at -70°C until use.

The FISH procedure was continued as follows: slides were
first brought to room temperature.

Then, the cells were

incubated for 3 minutes in 70% formamide/2X SSC, pH 7.0 at
70-75°C to denature the DNA.

The cells were washed in cold

50% ethanol, cold 70% ethanol and cold 95-100% ethanol,
each for two minutes.

While the cells were being washed,

the probe mix was prepared by combining the following:
Labeled probe

lp.1 of each

Hybridization Buffer (60% formamide/
2X SSC/10% dextran sulfate)
MBG water

7pl
lp.1

The probe mix was denatured for 5 minutes at 8 0°C on a hot
block and placed on ice.

Slides were removed from the
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ethanol and air-dried.

Ten microliters of the probe mix

was placed on each slide; the slide was covered with a
22x22mm glass cover slip and sealed with rubber cement
(Ross) .

Hybridization followed for 2-24 hours in a 37°C

incubator.
Upon completion of hybridization, stringency washes were
performed on the cells using the following procedure: three
washes of fresh 50% formamide/2X SSC, pH 7.0, each for 5
minutes at 42°C, followed by one wash in 2X SSC, pH 7.0 for
5 minutes at 42°C, followed by one wash in 4X SSC/0.05%
Tween 20, pH 7.0 for 5 minutes at 42°C and ending with one
wash in 4X SSC/0.05% Tween 20, pH 7.0 for 5 minutes at room
temperature.

The cells were incubated in a solution of 4X

SSC/0.05% Tween 20/0.05% blocker for 20 minutes at room
temperature.

While incubating, the conjugate mixes were

prepared as follows:
Anti-DIG:

10pl anti-digoxygenin rhodamine,
(200ug/ml)

(Boehringer Mannheim)

490pl 4X SSC/0.05% Tween 20/0.05%
blocker
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Avidin-FITC:

lpl fluorescent NeutrAvidin-FITC
conjugate,

(lmg/ml)

(Molecular

Probes)
499y.l 4X SSC/0.05% Tween 20/0.05%
blocker
Conjugate mixes were centrifuged for 5 minutes at 12,000 x
g, and the supernatant was collected.

Then, 10pl of each

conjugate mix was added to the cells, the cells were
covered with Parafilm M

(American National Can) and

incubated for 30 minutes in a dark, moist chamber at 37°C.
Finally, the cells were washed in three washes of fresh 4X
SSC/0.05% Tween 20, each for 5 minutes at room temperature.
Once washing was complete, the slides were removed and
excess fluid was drained.

Ten microliters of diluted DAPI

(4', 6-diamidino-2-phenylindole) was applied to the slide,
the cells were covered with a 22x22mm glass cover slip, and
viewed using a Nikon fluorescent microscope with cooled CCD
camera.

CALCULATION OF THE MITOTIC INDEX (MI)

% MI =

(# cells in metaphase / total # of cells)*100
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ISOLATION OF RNA FROM BONE MARROW

The TRIZOL® procedure from Life Technologies was used in
this study according to the manufacturer's directions.
brief,

In

0.5ml bone marrow sample was placed into a

microcentrifuge tube.

The cells were centrifuged and the

supernatant was discarded.

TRIZOL® Reagent was added

followed by a brief incubation at room temperature.

Then,

chloroform (Fisher) was added and the sample was again
incubated at room temperature,

followed by centrifugation

to separate the sample into distinct layers.

The upper

aqueous layer was recovered, and isopropyl alcohol
was added to precipitate the RNA.
held at room temperature,

(Fisher)

The sample was briefly

followed by centrifugation.

The

supernatant was discarded and the RNA pellet was dried, and
then re-dissolved in MBG water.

The optical density, at

260nm, of the dissolved RNA was recorded using a
spectrophotometer,

and the RNA concentration was calculated

from the relationship that 40p.g/ml RNA = 1.00 OD 2 6 0 .

REVERSE TRANSCRIPTION OF RNA

The commercially available reverse transcription system
from Promega was used during this study according to the
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manufacturer's instructions.

Briefly, MBG water, magnesium

chloride, RT 10X Buffer, dNTP mixture, Recombinant RNasin®
Ribonuclease Inhibitor, AMV Reverse Transcriptase,
Oligo (dT) 15 Primer, and l.Opg of total RNA were combined.
The sample was incubated at 42°C for 30 minutes,

followed

by a 5-minute incubation at 99°C, and another 5-minute
incubation on ice.

The newly synthesized cDNA was stored

at -20°C until further use.

POLYMERASE CHAIN REACTION (PCR)

A set of two primers

(Gibco BRL) were used to amplify the

first 1214 base pairs of the hBUBl coding region.
area included the CD1 region and the NLS region.
primer set used was

This
The

(Cahill, personal communication):

Primer 1

Forward 5' -CATGGACACCCCGGAAAATGTC-3'

Primer 2

Reverse 5' -GCATCTTTGCTGGCCACTGC-3'

Primer 1 was located at base pairs 4 9 through 70, and
primer 2 was located at base pairs 1244 through 1263 in the
consensus hBUBl sequence.

PCR was accomplished using the

Epicentre MasterAmp™ Taq DNA Polymerase and the following
protocol,

in brief, according to the manufacturer's

instructions.

MBG water,

10X PCR Buffer, magnesium

chloride, dNTP, forward PCR primer, reverse PCR primer, Taq
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DNA Polymerase, and the cDNA template were combined in a
PCR reaction tube.

Seventy microliters of mineral oil was

added to each PCR reaction tube, and the PCR reaction was
completed using the following program specific for hBUBl
PCR:
1. 95°C for 1 minute
2. 95°C for 30 seconds
3. 56°C for 30 seconds
4. 70°C for 2 minutes
5. Repeat to step 2, 35 times
6. 70°C for 5 minutes
7. Hold at 4°C
PCR results were viewed on a 1% agarose
TBE

(Sigma) gel in IX

(Tris-borate EDTA) stained with diluted ethidium

bromide.

ISOLATION OF DNA FROM AN AGAROSE GEL

The Geneclean kit from BIO101 was used with the following
protocol according to the manufacturer's directions.

In

brief, the PCR products were electrophoresed on a 1%
agarose gel in IX TAE (Tris-Acetate-EDTA), excised from the
gel and weighed.

6M Sodium Iodide (Nal) was added, and the

gel/Nal mixture was incubated in a 55°C water bath until
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the gel was completely dissolved.

Glassmilk (BIO101) was

added to each tube and the samples were vortexed,

followed

by a 5-minute incubation at room temperature and
centrifugation.

The supernatant was discarded and a series

of three washes were performed.
were air-dried,

The washed glassmilk beads

followed by the addition of TE buffer and

incubation for 5 minutes at 5 5 °C to elute the DNA.
glassmilk beads were pelleted by centrifugation,

The

followed

by recovery of the supernatant, which was stored at -20°C
until further use.

LIGATION OF DNA INTO A PLASMID VECTOR

A commercial pGEM®-T vector ligation kit from Promega was
used for this study with the following protocol using the
manufacturer's instructions.

Briefly, MBG water, 2X Rapid

Ligation Buffer, pGEM®-T Vector, T4 DNA Ligase and PCR
product DNA were combined and incubated for 1 hour at room
temperature or overnight at 4°C.

The ligated DNA was

stored at -20°C until use.
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MEDIA PREPARATION

LB (Lennox) media was used throughout this study, both in
broth and agar forms

(preparation described in Chapter II,

Solutions).

TRANSFORMATION OF LIGATED DNA

The procedure for transformation was as follows according
to directions provided by Promega, with one exception noted
below.

LB/Amp/IPTG/X—Gal plates were prepared and brought

to room temperature.

The ligated PCR product DNA:pGEM®-T

Vector was combined with High Efficiency JM109 Competent
Cells followed by incubation on ice for 20 minutes.
cells were heat-shocked,
on ice.

The

followed by a 2-minute incubation

LB broth was added to each tube, and the bacterial

culture was incubated for 1 hour in a 37°C shaker.

0.5ml

of the culture was spread onto a LB/Amp/IPTG/X-Gal plate
(the amount of the culture that was spread onto the agar
plate was changed from original protocol).
incubated

The culture was

overnight in a 37°C incubator, and blue-white

screening was performed to verify the presence of the
inserted DNA within the bacterial vector.
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As an additional step to verify the presence of and the
size of the inserted DNA, another round of PCR was
performed using the bacterial DNA from one white colony as
the template.

PCR was performed using the protocol

outlined in Chapter II, Polymerase Chain Reaction.

PLASMID DNA PURIFICATION

The OIAprep Spin Miniprep Kit from Qiagen was used to
purify the plasmid DNA.

The protocol was as per the

manufacturer, and is outlined in brief.

LB broth and

Ampicillin (Sigma) were placed into a centrifuge tube,
inoculated with one PCR-verified white bacterial colony,
and incubated overnight in a 37°C shaker.

The bacterial

cells were pelleted, and lysed via alkaline lysis.

The

sample was centrifuged, and the supernatant was applied to
a QIAprep spin column (a silica-based column included in
the Qiagen kit).

The column was centrifuged, followed by a

series of washes to remove contaminants.

Adding MBG water

to the column and centrifuging eluted the DNA, which was
stored at -20°C until use.
JM109 competent cells
transformation reaction.

(Promega) were used in the
The JM109 cells have high levels

of nuclease activity, which can interfere with subsequent
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sequencing reactions.

However, one of the washing steps

(above) removes excess nucleases, enabling

the purified DNA

to be used successfully in later sequencing- reactions.

RESTRICTION ENZYME VERIFICATION

Prior to sequencing, a final verification was performed
to ensure the proper size fragment was b e i n g sequenced.

A

restriction enzyme digest of the purified p l asmid DNA was
accomplished using SacI

(Promega)

and SacII

(Promega)

enzymes, which excised the insert from the vector without
cutting the insert itself.

The protocol w a s as follows

according to the package insert provided b y Promega.
water, plasmid DNA, 10X Multi-Core Buffer

MBG

OCPromega),

Acetylated BSA (Promega), SacI and SacII w e r e combined and
the sample was incubated in a 37°C water b a t h for one hour.
The restriction enzyme digest was viewed viLa
electrophoresis on a 1% agarose gel in IX U B E stained with
ethidium bromide.

SEQUENCING OF THE hBUBl GENE

Sequencing was accomplished using an ALF Automated DNA
Sequencer (Amersham Pharmacia Biotech).

Tluis sequencer
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reliably sequences 500 base pairs.

Since the hBUBl RT-PCR

product was 1.2kb, internal primers were incorporated to
break the 1.2kb product into three 400 base pair products
(Figure 7).

These shorter products were easily sequenced

by the ALF Automated DNA Sequencer.
labeled with Cy-5
the manufacturer

All primers were

(sequencer requirement)

and purified by

(Integrated DNA Technologies,

Inc.) using

HPLC to remove unincorporated dideoxynucleotides.

The

primers used were as follows (Cahill, personal
communication):
Primer 1

Forward 5' -AGGGTTTTCCCAGTCACGAC-3'

Primer 2

Forward 5' -CCTCTGTACATTGCCTGGGC-3'

Primer 3

Reverse 5' -TATTTCTGGGCTCTCAATTCTTC-3'

Primer 4

Reverse 5' -CACACAGGAAACAGCTATGAC-3'

Primers 1 and 4 were located within the plasmid vector
sequence, primer 2 was located at base pairs 347 through
3 66 in the consensus hBUBl sequence and primer 3 was
located at base pairs 803 through 825 in the consensus
hBUBl sequence.

Additionally, polyacrylamide gels designed

for longer base pair sequencing were used
Read by Amersham Pharmacia-Biotech) .

(Repro-Gel Long

The Epicentre

SequiTherm Excel II Long Read DNA Sequencing Kit for ALF
DNA Sequencers was used for the sequencing reaction
according to the manufacturer's directions with exceptions
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hBUBl
A ) PCR
P C R Forw ard Prim er
base pairs 49-70

CD1

CD2 3446

NLS
P C R Reverse P rim er
base pairs 1244-1263

B) Sequencing
Sequencing
P rim er 1
plasmid
vector area
►

Sequencing
P rim er 2
base pairs
3 47-366

1214
Sequencing
P rim er 3
base pairs
803-825

Figure 7.

Sequencing
Prim er 4
plasmid
vector area

hBUBl PCR and Sequencing Primer Locations

(A) The PCR primers spanned the CD1 and NLS regions of the
hBUBl gene. A total of 1214 base pairs were amplified by
PCR.
(B) Sequencing was accomplished using a set of four
primers.
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noted below.

In brief, a stock DNA template solution of

100fmol/p.l was prepared using the following two step
formula: 1) the number of picomoles per microliter was
calculated, using the following formula, where N = the
number of base pairs in the insert:
[DNA] y.g/y.1 x 106 x 1/660 x 1/N = pmol/pl
2) one picomole of DNA was aliquoted into a microcentrifuge
tube and MBG water was added to a final volume of lOy.1,
resulting in a stock solution of 100fmol/y.l (the creation
of a stock DNA template was not required in the original
protocol).

Then, MBG water, stock DNA template, sequencing

buffer and labeled primer were combined to form a premix
solution.

For each reaction,

were labeled A,C,G or T.

four microcentrifuge tubes

Termination Mixes were added to

each of the four tubes, followed by the addition of the
premix solution.

Mineral oil was added to each tube, and

the reactions were heated for 5 minutes at 95°C, followed
by 30 PCR cycles according to the program provided my
Epicentre.

Stop/Loading Buffer was added to each reaction,

and the reactions were incubated for 5 minutes at 95°C.
Seven microliters of each reaction was loaded onto the
sequencing gel (the amount loaded onto the sequencing gel
was changed from the original protocol.

The sequencer was

run using the following parameters at constant power:
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1000 minute run
1500 volts
60 milliamps
25 watts
55°C

PCGene SEQUENCING ANALYSIS

The PCGene computer program was used to analyze all
sequencing results.

Alignment and translation of

nucleotide sequences into corresponding amino acid
sequences was also performed.

STATISTICAL ANALYSES

Statistical analyses were performed using the SPSS
statistical analysis program.

Two-sample t-tests and

mulitivariate analysis of variances

(ANOVA) were performed.

Chi-squared analyses were computed using Microsoft Excel.
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C H A P T E R III
R ESULTS

SERIES A

Series A Patient: Data
Series A consisted of patients with AA and controls.

AA

was chosen because of the controversy of whether or not AA
is a pre-leukemic disorder.

All bone marrow samples in

series A underwent both FISH analysis for chromosomes 7 and
8 and sequencing of the hBUBl RT-PCR product.

Bone marrow

from 4 6 patients and six controls were analyzed in series
A.

Twenty-two out of 46 (47.8%) patients were male and the

remainder (24; 52.2%) were female.

The ethnic distribution

of patients in series A was as follows: 4 patients

(8.7%)

were of Asian descent, 5 (10.9%) were African-American,
(19.6%) were Hispanic and 24
four A A patients,

(52.2%) were Caucasian.

9

In

ethnicity was not reported (Figure 8).

All patients had a complete karyotype performed by the
National Institutes of Health in Bethesda, Maryland (Table
1).

All controls had a normal karyotype and no current or

previous history of hematological disorders.
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Figure 8.

Ethnic Distribution of Patients in Series A

Series A consisted of patients with AA. Series A samples
underwent both FISH for chromosomes 7 and 8 and sequencing
of the hBUBl RT-PCR product.
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Table 1. Karyotype Analysis of Patient Samples in Series A
Patient #
Karyotype Result
29
31
33
37
39
40
41
42
43
52
57
58
60
64
77
81
82
85
86
87
88
90
95
98
99
101
111
113
115
116
117
121
128
129
130
137
139
142
146
147
153
157
166

46, xy
46, xy
46, xy
46, xy [29]
4 6, xy
46,x x [31]
4 6, xx
46,x y [30]
46,x x [30]
47, xy,+8[13]/46,xy[7]
46, xy
46, xy
46,x,ins(x;1 ) (pll.4;q21q42.3)[9]/46,xx[41]
4 6,x x [30]
4 6,x x [30]
46, xy
46,y,t(x;8) (p22.1; q24 .1)
4 6, xx
46, xy
4 6, xx
46,x y [30]
4 6, xx
4 6, xx
4 6,x x [30]
47.xy,+8[14]/4 6,xy[7]
4 6,x,-y [14]/4 6, x y [6]
46, xy [30]
46, xx
4 6, xx
4 6,x x [30]
4 6,x x [30]
46, xy
4 6,x x [30]
4 6,x x [30]
4 6, xx
46, xx [30]
4 6, xx
4 6,x x [30]
4 6,x y [21]
46,x y [30]
46, xx
4 6,x y [30]
46,x y [30]
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Table 1 Continued.
Patient #
Karyotype Result
167
168
169

48,xxxc,+8[5]/47,xxxc[15]
Trisomy 8
4 6, xy

The patient number is listed with the corresponding
karyotype analysis information.
Seven patient samples
(15.2%) showed an abnormal karyotype.
The numbers in
brackets [] indicate the number of cells counted.
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FISH Analysis for Chromosomes 7 and 8 on Series A Patient
Samples and Control Samples
Nick translation was used to incorporate labeled
nucleotides into DNA to be used as probes FISH.
Fluorescently labeled alpha-satellite DNA probes were used
to detect the centromeric region of chromosomes 7 and 8 in
a two-probe, two-color FISH analysis.

FISH was performed

on all patient samples in series A; 300 nuclei were
analyzed for each sample.
The nuclei were scored as "normal" if two signals for
each chromosome were present.

Occasionally, nuclei

contained multiple small signals joined by a thin
filamentous line (Figure 9).
as one signal.

These occurrences were scored

In cells undergoing DNA replication (S

phase), the centromeric region is elongated.

Alpha-

satellite DNA FISH probes bind to the centromeric region of
the chromosomes, and therefore may exhibit the appearance
of a thin filamentous line in cells currently undergoing S
phase

(Litmanovitch, et al., 1998; Mukherjee et a l ., 1992).

Any signals less than 1 diameter apart from each other were
scored as one signal; however, this was a rare occurrence.
To allow unbiased scoring, an independent person coded all
samples.

The code was broken only after the entire set of

samples was scored.

Each set included at least one control
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Figure 9.

FISH Analysis for Chromosome 7

Example of a normal cell containing two copies of
chromosome 7, with one copy presented as multiple small
signals joined by a thin line (arrow). In this example,
both cells were scored as normal, with each cell containing
two copies of chromosome 7.
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and one patient sample.
Two out of 46

(4.3%) patient samples showed statistically

significantly elevated levels of monosomy 7 (Figure 10,
Table 2) when compared to the control sample value of 1.55%
monosomy 7.

Bone marrow from patient 111 showed 4.0%

monosomy 7, and bone marrow from patient 128 showed 5.17%
monosomy 7.

There were no patient samples exhibiting

statistically significant levels of trisomy 7, where the
control sample value was 0.4 6% trisomy 7.

Two out of 46(

4.3%) patient samples showed statistically significantly
elevated levels of monosomy 8 (Table 2) when compared to
the control sample value of 2.13% monosomy 8.

Bone marrow

cells from patient 58 had 5.3% monosomy 8, while bone
marrow cells from patient 128 had 12.1% monosomy 8.

Four

out of 46 (8.7%) patient samples showed statistically
significantly elevated levels of trisomy 8 (Table 2) when
compared to the control sample value of 0.98% trisomy 8.
Bone marrow samples from patient 52 had 20.3% trisomy 8,
patient 99 had 29.3% trisomy 8, patient 116 had 3.3%
trisomy 8 and patient 168 had 10.3% trisomy 8.

Bone marrow

cells from patient 128 showed a high level of abnormality
in both chromosomes 7 and 8 (monosomy 7 and monosomy 8) .
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Figure 10.

FISH Analysis Showing Apparent Monosomy 7

This photograph shows the detection of monosomy 7 using
FISH in a metaphase cell. Only one signal is shown for
chromosome 7 (arrow), indicating apparent monosomy for that
chromosome.
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Table 2. Patient Samples in Se=ries; A Showing Elevated
Levels of Cytogenetic Abnormali-ties with Control Data
Patient # % Monosomy 7 % Trisomy 7 % Monosomy 8 % Trisomy 8
52
0.67
2.67
58
0 .00
2.00
99
0.67
0.00
0.67
111
4.00*
116
2.67
1 .00
128
0 .00
5.17*
168
1.67
0.00
♦Statistically Significant

0.33
5.33*
2.67
4.33
1.00
12.07*
4.00

20.33*
0.00
29.33*
2.67
3.33*
1.72
10.33*

Control ¥ % Monosomy 7 % Trisomy 7 % Monosomy 8 % Trisomy 8
Con
Con
Con
Ded
Ded
Ded

1
2
5
4
5
6

0.66
2.29
2.00
1.66
1.00
1.66

1.33
0.76
0 .66
0 .00
0.00
0.00

1 .66
6.10
1.33
1.00
0.33
2.33

0 .66
1.52
0 .66
1.33
1.00
0 .66

Percent aneuplo idy £or chromosomes 7 and 8 for patient
samples in series A, versus con.trol sample data, for
patient samples that showed a s tatistically significant
level of aneuploidy.
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In comparison with data obtained by karyotype analysis,
FISH detected abnormalities not detected by karyotype in 4
of 7 patient samples

(Table 3) .

This lead to the

conclusion that FISH is approximately twice as sensitive in
detecting cytogenetic abnormalities than karyotype analysis
in this study.

Analysis of the Mitotic Index (MI) in Patient Samples from
Series A and Control Samples
The MI is an indication of the cell cycle frequency.

For

this study, the MI was determined by counting the number of
cells in metaphase and dividing by the total number of
cells scored.

Cells were determined to be in metaphase if

individual chromosomes were visible

(such as Figure 10).

The MI was examined since, hypothetically, hBUBl would have
a higher level of expression in a population of cells
undergoing rapid division.

For this study, the MI was

calculated (Chapter II) simultaneously while performing
FISH analysis on unstimulated bone marrow cells.

The

average MI for control samples was 0.33%, while the average
MI for patient samples in series A was 0.44%.

There was no

statistically significant difference between the patient
and control samples
line, HL60,

(p=0.571).

A rapidly dividing cell

assayed by Dr. Michael Stacey, was found to
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Table 3. Karyotype versus FISH Results in Series A
Patients Showing Elevated Levels of Aneuploidy
Patient # FISH Result Karyotype Result
52
58
99
111
116
128
168

+8
-8
+8
-7
+8
-7
-8
+8

(20.33%)
(5.33%)
(29.33%)
(4.00%)
(3.33%)
(5.17%)
(12.07%)
(10.33%)

47,xy,+8[13]/46, x y [7]
46, xy
4 7.xy,+8[14]/46,xy[7]
46, xy [30 ]
4 6,x x [30]
46,x x [30]
trisomy 8 (exact number
not available)

Samples from patients 58, 111, 116 and 128 showed elevated
levels of chromosome abnormalities for chromosomes 7 and/or
8 . In these patients, the abnormalities were not detected
by karyotype analysis.
Numbers in brackets [] indicate the
number of cells.
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have a MI of 2.2% in exponentially growing cells, six times
higher than the control sample MI rate in this study
(Stacey, personal communication).

For this reason, HL60

cDNA was used as the positive control for the hBUBlspecific RT-PCR.

It is known that hBUBl is more abundant

during active cell division, therefore, a cell line (such
as HL60) with an increased number of cell divisions would
have elevated expression of hBUBl, allowing for easy
amplification in a RT-PCR reaction.

hBCZBl-Specific RT-PCR on RNA from Patient and Control
Samples in Series A
PCR was performed on cDNA, constructed from total RNA,
for all patients in series A.

Ten out of 46 (21.7%) series

A patient cDNA samples amplified the expected 1.2kb hBUBl
RT-PCR product (Figure 11).

cDNA from each patient sample

underwent two separate, but identical rounds of hBUBlspecific PCR for verification.

All 3 6 patient cDNA samples

showing no hBUBl RT-PCR product were re-analyzed by an
additional round of PCR using primers for the ubiquitously
expressed gene actin.

All 36 patient cDNA samples

(100%)

amplified the expected ~550 base pair actin PCR product,
verifying that each RNA sample was intact and not degraded
(Figure 12).
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1 2

3 4

5 6

7 8

1.6 kb

Expected
1.2 kb
hBUBlspecific
RT-PCR
product

1.0 kb

positive
control

9 10

Figure 11.

11

12 13 14 15 16

Gel Electrophoresis of hBUBl-specific RT-PCR.

Lanes 1 and 9 contain a 1 kb DNA ladder.
Lanes 2-5 contain
patient cDNA samples showing the expected ixBDBl-specific
RT-PCR product of 1.2kb.
Lanes 10-14 contain patient cDNA
samples showing no amplification of the hBUBl-specific RTPCR product.
Lane 15 contains the hBUBl-specific RT-PCR
reaction completed on cDNA from HL60, which was used as the
positive control.
Lane 16 contains the negative control,
and lanes 6-8 are empty.
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1.0 kb
0.5 kb

Figure 12.

.Expected
-550 bp
Actin PCR
product

Gel Electrophoresis of Actin PCR.

Lane 1 contains a 1 kb DNA ladder.
Lanes 2-7 contain
patient cDNA samples showing the expected Actin PCR product
of -550 base p a i r s .
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All 36 patient RNA samples that showed no hBUBl RT-PCR
product underwent a second round of cDNA synthesis. In the
second cDNA synthesis, an hBUBl oligonucleotide reverse PCR
primer (spanning base pairs 1195-1215 in the normal
consensus sequence) was used in place of the Oligo(dT)is
primer.

This was performed to ensure that the cDNA

synthesis began at the 3' end of the NLS region within the
hBUBl RNA, thereby increasing the likelihood of successful
cDNA synthesis provided that hBUBl was being expressed.
This ensured that cDNA synthesis could occur even if the
hBUBl RNA past the 3' end of the NLS region was degraded.
The cDNA synthesized using the hBUBl oligonucleotide
reverse PCR primer was subjected to a new round of hBUBlspecific PCR.

Once again, all 3 6 patient cDNA samples

showed no amplification of the hBUBl RT-PCR product
13).

(Figure

HL60, the rapidly dividing cell line, chosen as the

PCR positive control, consistently amplified the correct
1.2kb hBUBl RT-PCR product (Figure 11).
cDNA was synthesized from total RNA isolated from five
control bone marrow samples using the 01igo(dT)i5 primer.
hBUB 1-specific PCR was performed on the cDNA, and three out
of 5 samples
product.

(60%) amplified the correct 1.2kb hBUBl RT-PCR

The remaining two showed no hBUBl RT-PCR product.

Due to lack of material, the control samples did
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46 RNA samples from patients
in series A undergo cDNA
synthesis using the
Oligo(dT)15 primer

46 cDNA samples from
patients in series A
All undergo h B U B l-specific
PCR in duplicate

10 samples amplify the
expected 1.2 kb h B U B l
RT-PCR product (21.7% )

36 samples do not amplify
the expected 1.2 kb hBUB 1
RT-PCR product (78.3% )

36 samples undergo a
round of actin-specific PCR

All 36 samples amplify the expected
actin PCR product (100% )
(RNA is intact and not degraded)

All 36 patient samples undergo
cDNA synthesis again using
the hB U B l oligonucleotide
reverse PCR primer

All 36 new cDNA samples undergo
another round of h B U B l-s p e c ie
PCR in duplicate

36 samples do not amplify the
expected 1.2 kb h B U B l
RT-PCR product (100% )

Figure 13. Flow Chart for cDNA Synthesis and hBUBlspecific RT-PCR in Patient Samples from Series A
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not undergo PCR for actin or additional cDNA synthesis
using the hBUBl oligonucleotide reverse PCR primer.

To

provide more accurate results, the number of control
samples should be increased, however only five control
samples were available at the time of this study.

Sequencing of the hBUBl RT-PCR Product in Patient Samples
from Series A and Sequencing of the HL60 RT-PCR Positive
Control
The cDNA from the ten patient samples in series A that
exhibited the correct 1.2kb hBUBl RT-PCR product were
sequenced to look for base pair changes within the hBUBl
CD1 and NLS regions.

In addition, cDNA from the PCR

positive control HL60 was also sequenced.

Sequencing was

performed first 1214 base pairs, which spanned the first
conserved domain and the nuclear localization sequence in
the hBUBl gene

(Figure 14).

hBUBl is comprised of 3446

base pairs, and consists of 25 exons.

All base pair

changes are referenced according to their base pair
location within the entire hBUBl consensus sequence, as
reported by Cahill et a l . (1998).

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

82

CATGGACACCCCGGAAAATGTCCTTCAGATGCTGGTGAATGGGAAAGATACATACAGTG
GGTAGAAGAGAAT T TT C C TGAGAATAAAGAATAC T T GATAAC T T TAC TAGAACAT T TAA
TGAAGGAAT T T T TAGATAAGAAGAAATACCACAAT GACCCAAGAT TCAT CAGT TAT T GT
TTAAAATTTGCTGAGTACAACAGTGACCTCCATCAATTTTTTGAGTTTCTGTACAACCA
TGGGATTGGAACCCTGTCATCCCCTCTGTACATTGCCTGGGCGGGGCATCTGGAAGCCC
AAGGAGAGCTGCAGCATGCCAGTGCTGTCCTTCAGAGAGGAATTCAAAACCAGGCTGAA
CCCAGAGAGTTCCTGCAACAACAATACAGGTTATTTCAGACACGCCTCACTGAAACCCA
TTTGCCAGCTCAAGCTAGAACCTCAGAACCTCTGCATAATGTTCAGGTTTTAAATCAAA
TGATAACATCAAAATCAAATCCAGGAAATAACATGGCCTGCATTTCTAAGAATCAGGGT
TCAGAGCTTTCTGGAGTGATATCTTCAGCTTGTGATAAAGAGTCAAATATGGAACGAAG
AGTGATCACGATTTCTAAATCAGAATATTCTGTGCACTCATCTTTGGCATCCAAAGTTG
ATGTTGAGCAGGTTGTTATGTATTGCAAGGAGAAGCTTATTCGTGGGGAATCAGAATTT
TCCT T TGAAGAAT TGAGAGCCCAGAAATACAAT CAACGGAGAAAGCAT GAGCAAT GGGT
AAAT GAAGACAGACAT TATAT GAAAAGGAAAGAAGCAAAT GCT T T TGAAGAACAGCT AT
TAAAACAGAAAATGGATGAACTTCATAAGAAGTTGCATCAGGTGGTGGAGACATCCCAT
GAGGATCTGCCCGCTTCCCAGGAAAGGTCCGAGGTTAATCCAGCACGTATGGGGCCAAG
TGTAGGCTCCCAGCAGGAACTGAGAGCGCCATGTCTTCCAGTAACCTATCAGCAGACAC
CAGTGAACATGGAAAAGAACCCAAGAGAGGCACCTCCTGTTGTTCCTCCTTTGGCAAAT
GCTATTTCTGCAGCTTTGGTGTCCCCAGCCACCAGCCAGAGCATTGCTCCTCCTGTTCC
TT T GAAAGCCCAGACAGTAACAGACTCCATGT T TGCAGTGGCCAGCAAAGATGC
Figure 14.

Consensus Sequence of the hBUBl RT-PCR Product

Underline indicates a PCR primer location.
an internal sequencing primer location.

Bold indicates
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Initially, direct-from-PCR sequencing was attempted to
reduce artifacts and preparation time.

However, results

from direct-from-PCR sequencing reactions were of poor
quality when compared to results obtained by cloning first.
For that reason,
this study.

cloning prior to sequencing was used for

Sequencing was accomplished by cloning the PCR

product into a plasmid vector, transformation of the
ligated PCR product and purification of the plasmid DNA.
However, a disadvantage encountered when cloning each
colony contains only one of the two alleles.

Therefore,

each sequence obtained represents only one of the two hBUBl
alleles present.

This issue can be resolved by sequencing

multiple colonies from the same reaction to ensure that
both alleles are sequenced.
Due to variations in the amount of extracted nucleic
acids, each sample underwent a different number of reverse
transcription reactions, PCR reactions and/or sequences.
Ideally, each individual patient RNA sample would have
undergone five separate reverse transcription reactions.
Each of the five resulting cDNAs

(per patient)

would have

undergone separate rounds of hBUBl-specific PCR.

Finally,

each PCR reaction would have been separately cloned and
sequenced.

The end result would have been five separate

sequences for each patient sample, and a confidence
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interval of 80%.

Statistically, 20 separate cDNA

syntheses, PCR reactions and sequences should be performed
on each patient sample to establish a confidence interval
of 95%

(Cahill, personal communication).

Artifacts can be

introduced at the reverse transcription stage, the PCR
stage, or during sequencing.

However, by increasing the

number of RT-PCR and sequence analyses, the likelihood of
error is reduced.

The maximum possible number of RT-PCR

and sequencing replications were performed on each patient
sample in an effort to rule out potential artifacts.

Each

patient sample underwent between one and seven RT-PCR and
sequencing reactions, depending on the sample availability.
In addition, since each bacterial colony contains just one
of the two hBUBl alleles, every time a colony was
sequenced,

there was a 50/50 possibility of sequencing

either allele.

In the instances where only one sequence

determination was performed and shown to be normal,

it is

possible that the other allele could have been mutant,
vice versa.

and

In these cases, the results obtained were

inconclusive.
RNA from patient 42 underwent one round of RT-PCR and
sequencing.

Since only one RT-PCR and sequencing reaction

was performed,

the power of the results was reduced,

therefore the results should be evaluated cautiously.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

and

85

Sequencing of hBUBl in the RT-PCR product sample from
patient 42 indicated two base pair changes located at base
pairs 824, 924 and an insertion.

The insertion consisted

of 11 extra base pairs inserted within the oligonucleotide
forward PCR primer sequence.
insertion,

if any, is unknown.

The significance of this
Due to the lack of

additional sequence information, the preliminary results
for patient 42's sample are inconclusive

(Figure 15, Table

4) .
RNA from patient 43 underwent one round of RT-PCR and
sequencing.

Sequencing of the hBUBl RT- product indicated

two base pair changes at base pairs 845 and 117 0.

Again,

due to the lack of additional sequence data, concrete
conclusions cannot be drawn (Figure 16, Table 4).
RNA from patient 52 underwent two separate rounds of RTPCR (PCR #1 and #2).

When sequenced, the DNA recovered

from PCR #1 showed no base pair changes, while the DNA
recovered from PCR #2 showed a base pair change at base
pair 472 and an insertion/deletion. The insertion was very
similar to the insertion found in patient sample 42, and
consisted of 12 extra base pairs inserted within the
oligonucleotide forward PCR primer sequence,
five base pair deletion.
insertion/deletion,

followed by a

The significance of this

if any, is unknown.

A preliminary
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Patient 4 2
RNA Sam ple

R T #1 - 5 / 5 / 9 9

P C R #1 - 8 /1 0 /0 0

Ceneclean 8 /2 4 /0 0

Ligate 9 /1 8 /0 0

Transform 9 /1 9 /0 0

Purify 9 /2 1 /0 0

Sequence 9 /2 2 /0 0

Result
2 base pair changes
(b p 8 2 4 & 927) and an insertion

Figure 15.

Sequencing Flow Chart for Patiemt 42

Preliminary results indicate two base pair changes and an
insertion.
However, these sequencing results were not
duplicated.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

87

Patient 4 3
RNA. Sample
R T
P C R

**1 - S / 5 / 9 9
**1 - 8/1 0 / 0 0

G e n e c l e a n 8/24/0 O
Ligate 8 / 2 8 / 0 0
T r a n sform 9/7/00
Pu r i f y 9 / 1 5 / 0 0
S e q u e n c e 9/22/00
Result
2 b a s e pair c h a n g e s
( b p 8 4 5 & 11 T O )

Figure 16.

Sequencing Flow Chart for Patient 43

Preliminary results indicate two base pair changes.
However, these sequencing results were not duplicated.
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observation is that the base pairs inserted within the
forward primer area in both patient samples are verysimilar to the base pairs from the plasmid vector, which
can be found immediately prior to the forward primer
starting point in the normal consensus sequence.

Perhaps

there was an error during ligation in which the ligation
area on the 5' end of the RT-PCR product was disturbed, or
the insertion(s)/deletion may be due to a polymerase error.
Due to the lack of additional sequence information, the
preliminary results for patient 52's sample are
inconclusive

(Figure 17, Table 4).

The RNA from patient 82 underwent two rounds of reverse
transcription.

The product from the first reverse

transcription reaction underwent one round of PCR (PCR #1) ,
followed by cloning and sequencing.

The product from the

second reverse transcription reaction underwent six
separate PCR reactions
sequencing.

(PCR #2-#7),

followed by cloning and

The DNA recovered from PCR #1 was sequenced

five times, which ruled out the possibility of a sequencing
artifact, however, the DNA from PCR #2-#7 was only
sequenced once.

The sequencing results from PCR #1 showed

four base pair changes located at base pairs 418, 532,
and 908.

632

The sequencing results from PCR #3 showed two

base pair changes located at base pair 711 and 1107.
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Patient 52
RNA Sample

Figure 17.

RT #1 -1/18/99

RT #2 - 5/5/99

PCR #1 - 1/22/99

PCR #2 - 8/10/00

Genedean 1/29/99

Genedean 8/24/00

Ligate 2/1 /99

Ligate 8/28/00

Transform 2/1/99

Transform 9/13/00

Purify 2/8/99

Purify 9/15/00

Sequence
2/12/99 and 2/16/99

Sequence 9/19/00

Result
No base pair changes

Result
1 base pair change
(bp 472) and an insertion/deletion

Sequencing Flow Chart for Patient 52

Preliminary results indicate one base pair change and an
insertion/deletion in the sequencing of DNA from PCR #2,
while the other sequence was normal, making the results
inconclus ive.
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sequencing results from PCR #4 showed one base pair change
at base pair 1177.

The remaining four PCR reactions showed

no base pair changes within their sequences.
base pair changes were seen in duplicate,
likely artifacts.

None of the

and were most

The RNA from patient 82 underwent the

most sequencing reactions

(seven in total) out of the ten

patient samples analyzed from series A.

The high level of

sequence variation in this patient sample showed that the
potential for artifacts was high among these experiments.
The overall sequencing data from patient 82's sample
indicated that the majority of sequences performed had no
base pair changes detected.

Therefore,

it is reasonable to

conclude that the remaining sequence variations were
artifacts

(Figure 18, Table 4) .

RNA from patient 90 underwent two rounds of RT-PCR and
sequencing.

Sequencing of both RT-PCR products showed no

base pair changes within the hBUBl sequence.
is reasonable to conclude, preliminarily,

Therefore,

it

that the sequence

data obtained from patient 90 is identical to the normal
consensus sequence data reported by Cahill et al (1998)
(Figure 19, Table 4).
RNA from patient 117 underwent one round of reverse
transcription followed by two separate PCR analyses.
PCR products were cloned and sequenced.

Both

The product from
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PCR H - 1/2/99

CeaedcM 6/21/00

G a te d c a i 6/21/00

G caedeia t/4/99

G o te d e to S/4/99

T tu u fo m t/9 /9 9

Seqoeace t/20/99

Resdt
4 base p a r diaages
(b p 4 H .5 3 2 .6 3 2 A 90S)

Figure 18.

Resalt
N o base p u r diaages

R em it
2 base p u r disages
(bp 711 & 1107)

Result
N o base p u r changes

Resvlt
N o base p u r dtasges

Result
No b tse p u r changes

Sequencing Flow Chart for Patient 82

Preliminary results indicate four base pair changes in the
sequence from PCR #1, 2 base pair changes in the sequence
from PCR #3, and 1 base pair change in the sequence from
PCR #4, all of which are different.
The remaining
sequencing reactions showed no base pair changes. These
results are contradictory.
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Patient 9 0
R N A S a m p I
#1

- 2/22/99

**1 - 4 / 1 2 / 9 9

# 2

- S/1 0 / 0 0

4/27"/99
Ligate 4/28/99
T r a n sfo

■4-/28/99

P u rity S / 1 3 / 9 9

Ligate 8/28/00
Transform

F»urrfy 9 / 1 S / O O

S e q u e n c e
S/31/99, S/8/99

R e s u i It
ISIo b a s e p a i r c h a n g e s

Figure 19.

9/13/00

11/1 /OO

INIo b a s e

R e s u It
pair c h a n g e s

Sequencing Flow Chart for Patient 90

Preliminary results showed both sequences with no base pair
changes, indicating that the sequence was the same as the
normal consensus sequence reported by Cahill et al., 1998.
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PCR #1 was sequenced six times and preliminary results
indicated that there were no base pair changes present in
any of the six sequencing reactions.

All six sequencing

reactions were performed on DNA from a single colony.

The

second PCR product was sequenced once, and one base pair
change was observed at base pair number 1055 in the hBUBl
normal consensus sequence.
conflicting,

The sequencing results were

showing a 50% probability that the sequence

obtained was normal and a 50% probability that the sequence
obtained contained a base pair change.

Considering the

high risk of artifacts in this study, it is possible that
the base pair change seen is in fact an error.
this point,

the data is inconclusive

However,

at

(Figure 20, Table 4).

RNA from patient 121 underwent three separate rounds of
RT-PCR (PCR #l-#3).

The DNA recovered from PCR #1 and #3

showed no base pair changes upon sequencing; however, the
DNA recovered from PCR #2 showed two base pair changes at
base pairs 615 and 1151.

The majority of the sequencing

data indicated that no base pair changes were present,
therefore there is a high probability that the two base
pair changes observed are artifacts.

It is reasonable to

conclude that patient 121's sample is most likely normal,
with no base pair changes present

(Figure 21, Table 4).
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Patient 117
RNA Sample

RT#1

F»CR #1

- 4 /1 5 /9 9

- 2 /2 2 /9 9

PCR # 2 - 8/10/00

Genedean 5/S/99

Genedean 8/24/00

l_igate 5/7/99

Ligate 8/28/00

Transform 5/7/99

Transform 8/30/00

Rurify 5/1 3/9 9

Rurify 9/1/00

Sequence 5/21/99,
8 /4/9 9 , 6/11/99,
6 /14 /9 9 , 6/17/99
and 1 0/8/99

Sequence 9/1 9/00

Result
No base pair changes

Result
1 base pair change
(bp 1 055)

Figure 20.

Sequencing Flow Chart for Patient 117

Preliminary results indicate one base pair change in the
sequence from PCR #2, with the other sequence as normal,
making the results inconclusive.
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P atient 121
R N A S am p le

R T #1 - 2 / 2 2 / 9 9

R T # 2 - 3/1 8 /0 0

R T # 3 - Aaron

P C R #1 - 4 / 1 5 / 9 9

P C R # 2 - 8/1 0 /0 0

P C R # 3 - 8/1 0 /0 0

G e n e d e a n 5 /6 /9 9

G e n e d e a n 8 /2 4 /0 0

G e n ed e an 8 /2 4 /0 0

Ligate 5 /7 /9 9

Ligate 8 /2 8 /0 0

Ligate 8 /2 8 /0 0

Transform 5 /7 /9 9

Transform 9 /7 /0 0

Transform 9 /7 /0 0

Purify 5/1 3 /9 9

Purify 9/1 5 /0 0

Purify 9/1 5 /0 0

Seq u ence
6 /6 /9 9 and 6/1 3 /9 9

Seq u ence
9 /1 9 /0 0 and 9 /2 0 /0 0

Sequence 9 /2 0 /0 0

Result
No base pair changes

Result
2 base pair changes
(bp 6 1 5 & 1 151)

Result
No base pair changes

Figure 21.

Sequencing Flow Chart for Patient 121

Preliminary results indicate two base pair changes in the
sequence from PCR #2, and no base pair changes in the other
two sequences, leading to the conclusion that the sequence
is most likely normal.
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The RNA from patient 129 underwent one round of RT-PCR
and sequencing.

Sequencing results showed no base pair

changes were present.

As with all patient samples that

were sequenced only once, the results are inconclusive
(Figure 22, Table 4).
RNA from patient 137 underwent two rounds of reverse
transcription.

The product from the first reverse

transcription reaction subsequently underwent two separate
rounds of PCR (PCR #1 and #2) , while the product from the
second reverse transcription reaction underwent only one
round of PCR (PCR #3).

When sequenced,

the DNA recovered

from PCR #1 showed no base pair changes present.

DNA from

PCR #2 showed five base pair changes located at base pairs
327, 844, 8 68, 975 and 1227.

The sequencing results from

the DNA recovered from PCR #3 showed one base pair change
at base pair 470.

As with patient 82, none of the base

pair changes were present in duplicate.

In addition, the

probability of six base pair changes occurring within 1214
base pairs is rare, and would indicate an extremely high
mutation rate.

If that were the case, the base pair

changes would have been detected in other samples and found
in duplicate.

The actual probability of this many

different base pair changes occurring is very low;
therefore, the base pair changes seen are most likely
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Patient 129
RNA Sample

RT *
*
-1 - 9/1 S /99

PCR #1 - 9/21/99

G enedean

L ig a te

"I "I / I 8 /9 9

1 1/ 3/0 O

ransform

P u rify

"I -i

S e q u e n ce

No base

Figure 22.

"I "I /3 /0 O

/~r/oo

"
11/"I 5 /0 O

R e s u It
pair- c h a n g e ;

Sequencing Flow Chart for Patient 129

Preliminary results indicate no base pair changes; however,
the lack of additional sequence information makes the
results inconclusive.
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artifacts.

Nevertheless, the sequencing data for patient

137 is conflicting, and a concrete conclusion cannot be
MADe

(Figure 23, Table 4) .

The RNA from patient 153 underwent one round of RT-PCR
and sequencing.

The sequence data for patient 153 showed

five base pair changes located at base pairs 645, 930, 931,
932 and 933.

The sequential base pair changes were unique

to patient 153, and were not seen elsewhere.

Due to the

lack of additional sequencing data, these results are
inconclusive (Figure 24, Table 4).
Sequencing of the HL60 hBUBl-specific RT-PCR product
revealed no base pair changes, and was consistent with the
normal consensus sequence reported by Cahill et al.

(1998).

Any potential polymorphism or mutation that does not result
in a change in the amino acid sequence, does not affect the
protein sequence. Therefore, any base pair change that does
not have a corresponding amino acid change would most
likely be inconsequential.
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Patieuit 137
RNA Sample

RT #1 -3/19/99

R T # 2 -Aaron

PCR #1 -4/15/99

PCR #2 -8/10/00

PCR # 3 -8 /1 0 /0 0

Genedean 5/6/99

Genedean 8/24/00

Genedean 8/24/00

Ligate 5/7/99

Ligate 8/28/00

Transform 5/7/99

Transform 8/30/00

Transform 9/7/00

Purify 5/13/99

Purify 9/1/00

Purify 9/15/00

Sequence

Sequence 9/19/00

Sequence 6/6/99

9/5/00 aned 10/26/00

Result
No base pair changes

Figure 23.

Re-suft

Result

5 base patir changes
(bp 327. 844. 8*68, 975 & 1227)

1 base pair change
(bp 470)

Sequencing Flow Chart for Patient 137

Preliminary results indicate fi_ve base pair changes in the
sequence from PCR #2, 1 base p a i r change in the sequence
from PCR #3 (all different) , a n d no base pair changes in
the sequence from PCR #1, making the results conflicting
and inconclusive.
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P a tie n t 153
R N A S a m p le

R T 9/1 5/9 9

P C R 9 /2 1 /9 9

G e n e d e a n 1 1 /2 2 /9 9

L ig ate 1 1 /3 /0 0

T ransform 1 1 /3 /0 0

Purify 1 1 /7 /0 0

S e q u e n c e 1 1 /1 5 /0 0

R esu lt
5 b ase pa ir changes
(b p 6 4 5 , 9 3 0 , 9 3 1 , 9 3 2 & 9 3 3 )

Figure 24.

Sequencing Flow Chart for Patient 153

Preliminary results indicate five base pair changes;
however, the lack of additional sequence information makes
the results inconclusive.
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Table 4. Summary of Base Pair Changes/Amino Acid Changes
in Patient Samples Sequenced from Series A with
Corresponding FISH Analysis
Patient # FISH Result PCR# BP# BP Change Amino Acid Change
42

Normal

#1

ins
824
937

43

Normal

#1

845 G-^A
1170 T-»C

Glu-^Lys
No change

52

+8 (20.33%)

#2

Protein unable
to be
translated

82

Normal

#1

#4

ins/ 12 bp
del ins/5
472 bp del
G-»A
418 G-»A
532 T-»C
632 G->A
908 C-»T
711 T-»A
1107 A->G
1177 A->C

No change
No change
Gly-^Arg
Gln->stop
Val-»Glu
No change
No change

#3

11 bp ins Protein unable
to be
T->C
translated
T-»C

117

Normal

#2

1055 A->T

Arg->stop

121

Normal

#2

615 A~>G
1151 G-»A

Gln-^Arg
No change

139

Normal

#2

327
844
868
975
1227
470

G-»A
T*>C
A-^G
A-»G
T->C
A->G

Gly*^Glu
No change
No change
Glu->Gly
Val~^Ala
Arg->Gly

645
930
931
932
933

C-»T
A-»G
T“»C
G->C
A->G

Ser^Leu
\
MetAspGluLeu~>
MetGlyArgLeu
/

#3
153

Normal

#1

Comparison of FISH data and sequencing results for hBUBl.
Abbreviations: BP=base pair ; ins:=insertion ; del=deletion
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Statistical Analyses on Data from Patient Samples in Series
A
Statistical analyses were performed using the SPSS
computer software program.

The data obtained from the FISH

analyses for aneuploidy rates in chromosomes 7 and 8 were
evaluated using a two-sample t-test.

The results showed

that there was no statistically significant difference
between the average level of aneuploidy in the patient
samples versus the control samples

(p=0.453 for monosomy 7,

p=0.194 for trisomy 7, p=0.840 for monosomy 8 and p=0.685
for trisomy 8).
To allow comparison of individual patient data and
control data, a chi-squared analysis was performed.

The

results from the chi-squared analysis show that two out of
46 patients

(4.3%) showed statistically significantly

higher levels of monosomy 7, two out of 4 6 patients

(4.3%)

showed statistically significantly higher levels of
monosomy 8 and four out of 4 6 patients

(8.7%) showed

statistically significantly higher levels of trisomy 8.
One patient sample showed elevated levels of both monosomy
7 and monosomy 8 (2.2%)

(outlined previously in Table 2).

A statistical comparison was performed to check the
effect of age, race, and responsiveness to treatment with
respect to aneuploidy.

An analysis of variance was
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performed using the SPSS computer program, and the only
statistically significant result showed that AfricanAmerican males were more likely to exhibit monosomy for
chromosome 8 (p=0.016), however the sample size was low.
Responsiveness to treatment and age of the patient did not
correlate with the level of aneuploidy for either
chromosome 7 or 8.

SERIES B

Series B Patient Data
One hundred and forty-three additional patient samples
underwent RT-PCR and sequencing analysis for hBUBl without
FISH analysis.

The patient samples in series B consisted

of 49 patients with AA,
with pancytopenia,

63 patients with MDS, 8 patients

6 patients with PNH, 3 patients with

anemia, 3 patients with PRCA, 3 patients with
thrombocytopenia,

2 patients with myeloproliferative

disease, 2 patients with neutropenia,
porvovirus,

1 patient with

1 patient with LGL, 1 patient in transformation

to leukemia and 1 patient with "liver transplant" as the
diagnosis

(Figure 25).

The sex of the patient was known

for 136 out of 143 patients; 52 out of 143 (36.4%) were
female and 85 out of 143 (59.4%) were male.

The ethnic
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Figure 25.
B Patients

Distribution of Bone Marrow Disorders in Series
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distribution of patients in series B show e d that eight out
of 143

(5.6%) were Asian, ten out of 3_43 (7.0%) were

African-American,
out of 143

13 out of 189 (9.1%)

(57.3%) were Caucasian.

were Hispanic and 82

I n 30 patients

ethnicity was not reported (Figure 26) .

(21.0%),

Sixty-eight

patients out of 143 (47.6%) had a complete karyotype
performed by the National Institutes o f Health in Bethesda,
Maryland (Appendix A) .

The remaining

75 patients did not

undergo karyotypic analysis.

hBDBl-Specific PCR on cDNA from Patients in Series B
PCR was performed on cDNA constructs f r o m all 143 patient
samples.

Twenty-one out of 143

(14.7g)

patient samples

amplified the expected 1.2kb hBUBl RT— PCR product.

One

hundred and twenty-two out of 143 (85 — 3%) patient samples
did not amplify a 1.2kb hBUBl RT-PCR product during the
first round of hBUBl-specific RT-PCR.

The cDNA used in the

first round of hBUBl-specific PCR was

synthesized using the

0ligo(dT)i5 primer.

Each PCR reaction was performed in

duplicate for verification of results-

All 122 patient

samples with no hBUBl RT-PCR product w e r e re-analyzed by
another round of PCR for the ubiquitoosly expressed gene
actin.

One hundred and sixteen out ofr 122

(95.1%) patient

samples amplified the expected ~500 b a s e pair actin PCR
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Figure 26.

Ethnic Distribution of Patients in Series B

Series B consisted of patients with, a variety of bone
marrow disorders (Figure 25) . Series B samples underwent
sequencing of the hBUBl RT-PCR product without FISH
analysis.
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product.

Six patient samples did not amplify any actin PCR

product.

Therefore, it was assumed that the six patient

samples that did not amplify the actin PCR product had
degraded RNA.

For the other 116 patient samples, the

correct amplification of the actin product verified that
the RNA was intact and not degraded.

All patient samples

that showed no hBUBl RT-PCR product, but did amplify the
expected actin PCR product underwent a second round of cDNA
synthesis.

In the second cDNA synthesis, the hBUBl reverse

oligonucleotide PCR primer was used in place of the
Oligo(dT)i 5 primer (Figure 27).

As stated in Chapter II,

the synthesis of new cDNA using the hBUBl oligonucleotide
reverse PCR primer was performed to increase the likelihood
of successful cDNA synthesis of hBUBl, provided that the
gene was being expressed.

The cDNA synthesized using the

hBUBl oligonucleotide reverse PCR primer was subjected to a
new round of hBUBl-specific PCR.

Twenty-two of the 122

patient samples that underwent the second round of reverse
transcription using the hBUBl oligonucleotide reverse PCR
primer,

followed by a second round of hBUBl specific PCR,

amplified the correct 1.2kb expected hBUBl RT-PCR product.
These samples were then combined with the patient samples
that showed amplification of the expected hBUBl RT-PCR
product during the first PCR reaction using the 01igo(dt)is
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hBUBl
RT-PCR with 01igo(dT)l5 primer

CD1

NLS

CD2 3446
01ig o (d T )ls R T -P C R prim er
c D N A synthesis starting point

RT-PCR with hBUBl reverse PCR primer
CD1

NLS

C D 2 3446
h B U B l reverse P C R prim er
c D N A synthesis starting point

Figure 27. hBiTBl-Specific RT-PCR Primer Locations
Graphical representation of the location of the RT-PCR
primers used in this study.
The 01igo(dT)is primer begins
cDNA synthesis at the poly A tail, whereas the hBUBl
reverse PCR primer, when used in reverse transcription in
place of the 01igo(dT)i5 primer, begins cDNA synthesis at
the 3' end of the NLS region in hBUBl.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

109

primer.

In total, 43 out of 143 samples

(30.1%) amplified

the hBUBl expected RT-PCR product in this additional
patient set

(Figure 28).

The 30.1% of patient samples from

series B that amplified the hBUBl RT-PCR product is
slightly higher than the 21.7% of patient samples from
series A that amplified the hBUBl RT-PCR product.
Potential reasons for the lack of hBUBl RT-PCR
amplification are discussed further later in this Chapter.

Sequencing of the hBUBl RT-PCR Product in Patient Samples
from Series B
Of the 43 patient samples that correctly amplified the
1.2kb hBUBl expected RT-PCR product,
sequenced.

14 were subsequently

All 14 samples underwent one round of reverse

transcription, PCR and sequencing.

Therefore, these

results must be viewed as preliminary.

Further sequencing

is necessary to increase the confidence interval, and
reduce the error introduced by only one sequencing reaction
performed for each patient.
Samples from patients 34, 80, 84, 96, 102, 108, 110, 133,
140, 144 and 179 showed no base pair changes present in the
CD1 or NLS regions of the hBUBl RT-PCR product.

Patient

46's sample showed one base pair change at base pair 726;
patient 132's sample showed one base pair change at base
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143 RNA samples from patients
in series B undergo cDNA
synthesis using the
Oligo(dT)15 primer

143 cDNA samples from
patients in series B
All undergo hBUB 1-specific
PCR in duplicate

21 samples amplify the
expected 1.2 kb h B U B l
RT-PCR product (14.7%)

122 samples do not amplify
the expected 1.2 kb h B U B l
RT-PCR product (85.3%)

122 samples undergo a
round of actin-specific PCR

6 samples do not amplify the expected
actin PCR product (4.9%)
(RNA is degraded)

116 samples amplify the expected
actin PCR product (95.1%)
(RNA is intact and not degraded)

116 patient samples undergo
cONA synthesis again using
the h B U B l oligonucleotide
reverse PCR primer

All 116 new cDNA samples undergo
another round of hBU81-specific
PCR in duplicate

94 samples do not amplify the
expected 1.2 kb h B U B l
RT-PCR product (81.0%)

22 samples amplify the expected
1.2 kb h B U B l RT-PCR product (19.0%)

Equals a combined total of
43 patient samples that
amplified the expected
1.2 kb h B U B l RT-PCR product (30.1 %)

Figure 28.
Flow Chart for cDNA Synthesis and hBUBlspecific RT-PCR in Patient Samples from Series B
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pair 566, and patient 136's sample showed two base pair
changes at base pairs 358 and 731

(Table 5).

Again, these

base pair changes were not seen in duplicate, and maylikely be artifacts.

Given the results from the previous

extensive sequencing, there was a high frequency of
potential artifacts

(see end of next paragraph).

Assessment of PCR Conditions
In sequencing patient samples from both series A and
series B, I was concerned by the high prevalence of base
pair changes in some samples.

The normal DNA mutation rate

is about one in 108 (0.0000001%) base pairs per cell
generation (Alberts et al., 1989).

Single nucleotide

polymorphisms occur in one out of every one to two thousand
base pairs

(Osgood, personal communication).

Therefore,

five or six base pair changes in a span of 1214 base pairs
is unusually high.

In a retrospective analysis, I noticed

that PCR reactions performed after August 20, 1999 were
completed using a different Taq DNA Polymerase.

The

protocol after August 20, 1999 utilized a lower grade of
Taq Polymerase in the PCR reactions.

A low grade Taq

Polymerase may have a higher frequency of error when
compared to a high quality Taq Polymerase, which has an
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Table 5. Summary of Sequencing Results and Diagnoses for
Patient Samples from Series B
Patient # Diagnosis
BP# BP Change Amino Acid Change
34

AA/PRCA

46

MDS

80

LGL

No base pair changes

84

MDS

No base pair changes

96

Transformation
to Leukemia

No base pair changes

102

MDS

No base pair changes

108

MDS

No base pair changes

110

MDS

No base pair changes

132

Liver
566
Transplantation

133

MDS

136

AA

140

MDS

No base pair changes

144

AA/Hepatitis B

No base pair changes

179

AA

No base pair changes

No base pair changes
726

C“»T

A-»G

Ala~>Val

Thr-»Ala

No base pair changes
358
731

T->C
A->G

No change
Lys~>Glu

Comparison of diagnosis for patients in series B to the
sequencing results obtained.
Abbreviations: BP=base pair
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error rate of about 3.2 mutations induced per 100,000 base
pairs

(0,0032%)

(Epicentre Technical Support, personal

communication) .

Due to the number of base pair changes in

sequences from PCR reactions completed prior to August 20,
1999 when compared to sequences from PCR reactions
completed after August 20, 1999, a retrospective analysis
was performed to compare these two subgroups.
In looking at the sequencing reactions performed, one can
divide the group of sequences into those that showed base
pair changes and those that did not show any base pair
changes

(Table 6).

Ignoring patient identifier data, and

only looking at the sequences as a whole,

it is obvious

that a large percentage of the sequences that exhibited one
or more base pair changes were completed after August 20,
1999.

In addition, the majority of sequences that showed

no base pair changes were completed prior to August 20,
1999

(Figure 29).

As a final observation, there is an

inverse correlation between the number of base pair changes
detected and my experience level with respect to
sequencing.

Therefore, these observations are not likely

the result of my inexperience with the sequencing protocols
and procedures.

The overall number of base pair changes

from patient samples in series A was 48 in 40,095 base
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pairs sequenced (0.12%), while samples in series B had 12
base pair changes in 23,085 base pairs sequenced (0.05%).
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Table 6. Comparison Between the Date of the Sequence and
the Sequence Result
Sequences Demonstrating No Sequences Demonstrating a
Base Pair Changes
Change in 1+ Base Pairs
10/8/99*
8/1/00*
8/20/99*
8/20/99+
8/17/99+
11/15/00*
6/6/99+
10/11/99*
11/01/00*
6/13/99+
9/20/00*
2/16/99+
6/7/99+
4/24/99+
6/7/99+
4/22/99+
4/13/00*
5/29/99+
11/15/00*
5/30/99+
5/29/99+
10/11/99*
5/19/99+

9/5/00*
6/14/99+
8/1/00*
8/17/99+
9/22/00*
10/26/00*
9/19/00*
9/20/00*
9/19/00*
9/22/00*
11/15/00*
12/6/00*
6/16/99+
6/16/99+

Comparison of sequencing results versos the date sequenced,
t Prior to August 20, 1999
* After August 20, 1999
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□ Before August 20, 1999 ■ After August 20, 1999

©

20

1+ Base Pair Change(s)

No Base Pair Changes

Figure 29. Graphical Representation of the Sequencing
Results Versus the Date of Sequencing.
These results indicate that more of the sequences that
showed 1+ base pair changes were performed after August 20,
1999.
Likewise, more of the sequences that showed no base
pair changes were performed prior to August 20, 1999.
This
indicates that the high rate of base pair changes may be a
direct result of the substitution of Taq Polymerase.
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CHAPTER IV
DISCUSSION

NEW INFORMATION ABOUT THE hBUBl GENE

Since the inception of this study, many advances have
been made with regards to the status of the hBUBl gene in
various cancers/cancer cell lines.

The index cases were

reported by Cahill et a l ., who found two of 19 (10.5%)
colorectal cancer cell lines exhibited a mutation within
hBUBl.

The first mutation was a 197 base pair deletion

spanning codons 76-141, and the second was a missense
mutation (C-^A transition at codon 492 resulting in an amino
acid change of Tyr->Ser)

(Figure 30) .

Both mutations were

found to be heterozygous, with a wild type second allele.
When either mutation was expressed in a cell, the cell
changed to a CIN phenotype,
were dominant negative

indicating that the mutations

(Cahill et a l ., 1998) .

It is

important to note that the original colorectal cancer cell
lines that exhibited a hBUBl mutation all had a CIN
phenotype and exhibited high levels of aneuploidy (30-50%)
in many different chromosomes, including chromosomes 7 and
8 (Cahill et al., 1998; Lengauer et al.,

1997).
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of aneuploidy is about 10 times higher than the observed
average aneuploidy in this study for chromosomes 7 or 8.
In addition, only one patient sample showed an elevated
level of aneuploidy in both chromosomes 7 and 8.

In

contrast, the cell lines examined by Cahill et a l ., showed
consistently high levels of aneuploidy in all chromosomes
analyzed (Cahill et al., 1998; Lengauer et al., 1997).
Yamaguchi et al. studied 31 head and neck squamous cell
carcinoma and lung cancer cell lines with respect to
mutations within hBUBl, and found only one base pair change
present

(T->C transition at codon 220 with no amino acid

change)

(Figure 30).

This implies that mutations in hBUBl

within head and neck squamous cell carcinoma or lung cancer
cell lines are rare, and do not contribute to the high
levels of aneuploidy that is characteristic of these cell
lines

(Yamaguchi et al., 1999).

Imai et al. examined 32 sporadic digestive tract cancers
for mutations within the hBUBl coding region, and found one
heterozygous mutation within hBUBl in one rectal cancer
case

(A-^G transition at codon 950 with an amino acid change

of Gly-^Ser)

(Figure 30).

This data indicates that

mutations within hBUBl are not common in the sporadic
digestive tract cancers

(Imai et al.,

1999).
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CD1

1

*—
Cahill et aL, 1998
CD1

NLS
*
Yamaguchi et al., 1999
CD1

CD2 1148

NLS

NLS

*

CD2 1148

CD2 1148
*

Imai et al., 1999
CD1

1

NLS

CD2 1148

Oshima et al., 2000

Figure 30.

Comparison of Mutation Locations for hBUBl.

The four studies that have shown the presence of a mutation
within the hBUBl coding region are shown here.
Each
mutation is marked with the * symbol at the approximate
codon location that the mutation occurred.
None of the
mutations occurred in the same location.
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Myrie et al. looked at 19 breast cancer cell lines, all
of which were aneuploid, and found no mutations present in
the hBUBl coding region.

Therefore, mutations in hBUBl

within breast cancer cell lines are a rare event.
Ohshima et al. analyzed ten cases of adult T-cell
leukemia and eight cases of B-cell lymphoma for mutations
in hBUBl, and found one mutation in one of the adult T-cell
leukemia patients

(G“^A transition at codon 250 with an

amino acid change of Gly^Asp)

(Figure 30) .

Mutations in

hBUBl were not common in either adult T-cell leukemia or 13cell lymphoma, and most likely do not contribute to the
highly complex karyotypes seen in patients with adult Tcell leukemia (Ohshima et al., 2000).
It is also interesting to note that Jaffrey et a l .
examined the stability at seven microsatellite markers on
chromosome 2q (where hBUBl is located)

in 32 colorectal

cancers and 20 non-small cell lung cancers, both of which
exhibit high levels of aneuploidy.

The BUB1 locus was

found to be allelically unstable in 62.5% of colorectal
cancer samples examined.

Instability can result in changes

within the coding region, which affects gene transcription.
In addition, the hBUBl sequence was analyzed in these 32
colorectal cancer tumors, 20 non-small cell lung cancers,
and 8 colorectal cancer cell lines, and no mutations were
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present.

This indicates that mutations within hBUBl are

most likely not responsible for the high levels of
aneuploidy that is commonly seen in colorectal cancer
tumors, non-small cell lung cancers and colorectal cancer
cell lines

(Jaffrey et al., 2000).

In combination, the data summarized above indicate that
mutations in the hBUBl coding region in a variety of
cancers and cancer cell lines are very rare occurrences.
The information from this study is in agreement with the
above data, and showed that a mutation within hBUBl in
samples from patients with aplastic anemia is also a rare
occurranee.

FISH RESULTS

The presence of clonal cytogenetic abnormalities in
patients with AA is evidence of a pre-leukemic state
and Geary, 1991).

(Marsh

Some researchers have shown that

cytogenetic analysis by FISH is more sensitive than
karyotype analysis

(Thurston et al., 1999; Socie et al.,

2000; Young, 1999; Young, 2000).

Therefore,

FISH may

detect early clonal cytogenetic abnormalities normally
missed by a karyotype analysis.

Since monosomy 7 and

trisomy 8 are common in MDS and ANLL (Socie et al., 2000),
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chromosomes 7 and 8 were chosen for FISH analysis in this
study.

Hypothetically, the presence of chromosomal

aberrations may indicate a higher likelihood of later
transformation to MDS or ANLL.

These aberrations may be

easier to detect using FISH.
The statistical analyses on the results obtained by FISH
analysis on bone marrow samples from patients in series A
(AA patients only), showed no statistically significant
difference between the patient samples as a whole versus
control samples with respect to the level of aneuploidy for
either chromosome 7 or 8.

There were certain patient

samples that individually showed increased levels of
aneuploidy in chromosome 7, chromosome 8 or a combination
of both chromosomes.

Seven of 46 patient samples

showed increased levels of aneuploidy.
patient samples

(15.2%)

Four of the seven

(57.1%) showed newly detected aneuploidy

that was previously unreported in a karyotype analysis.
FISH may be useful in detecting chromosomal abnormalities
earlier within the disease progression.

In this study,

FISH results were more than twice as sensitive in detecting
cytogenetic abnormalities when compared to the results
obtained by a karyotype analysis.
The level of aneuploidy in patient samples that showed
statistically significant levels of aneuploidy ranged from
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3.33% to 12.07%.

These values are relatively low when

compared to literature values for aneuploidy levels found
in colorectal cancer cell lines

(30-50%).

In addition,

values reported by Lengauer et a l . demonstrated a high
level of aneuploidy in all chromosomes assayed, not
selective aneuploidy in just one or two chromosomes.
affects all chromosomes equally"

"CIN

(Lengauer et al., 1997),

however, of the seven patient samples showing statistically
significantly elevated levels of aneuploidy, only one
patient sample showed an increased level of aneuploidy for
both chromosomes 7 and 8.

The remaining six patient

samples showed selective aneuploidy in only one of the two
chromosomes assayed.
The mitotic index, obtained to estimate the cell growth
rate, was uniformly low and not statistically significantly
different in a 2-sample t-test comparison of patient
samples versus control samples

(p=0.571).

The patient

samples in this study do not appear to be rapidly dividing,
but neither do the control bone marrow samples.
al.

Cahill et

(1998) demonstrated that the mitotic index was

significantly reduced in cells that expressed a mutant
hBUBl.

The cells with wild-type hBUBl showed a mitotic

index that was 90% of the control value, while cells with a
mutant hBUBl showed a mitotic index that was 60% of the
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control value

(Cahill et al., 1998).

In comparison, the

data from this study (series A patient samples only)
indicated that the average patient MI was 0.44%, while the
average control MI was 0.33%.

These data are different

from the data previously reported by Cahill et al.

(1998).

However, in the study by Cahill et a l . (1998), pure
colorectal cancer cell lines were used, compared to the
cells in this study, which were taken from patients with
decreased bone marrow.

The low mitotic index may be of

importance when evaluating the hBUBl-specific RT-PCR
results from the patient samples in this study.

RT-PCR RESULTS

The absence of h-BCTBI-specific RT-PCR products in patient
samples from this study may have occurred as a direct
result of low cell regeneration.

In some samples, the

intensity of the expected RT-PCR band varied, indicating
that the level of hBUBl expression may vary from patient to
patient.

DNA microarray assays have detected that in

yeast, BUB1 peaks during the G1 phase of the cell cycle
(Spellman et al., 1998).

Perhaps those patients who did

not amplify any hBUBl RT-PCR product had a very low level
of hBUBl expression, or had the majority of the cells not
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in the G1 phase of the cell cycle, so that the level of
hBUBl was too low to be detected by conventional RT-PCR
methods.

The same concentration of RNA was used in all of

the cDNA synthesis reactions, however different volumes of
RNA were used in each reaction, depending on the
concentration of the RNA.

RT-PCR was successful in

amplifying the hBC7B2-specific RT-PCR product in samples
with an RNA concentration as low as 0 .0 62p.g/p.l.

On the

contrary, no hBC7B2-specific RT-PCR product was detected in
samples with an RNA concentration as high as 4.440p.g/y.l.
If hBUBl were expressed in dividing cells, one would
expect successful amplification of the hBUBl RT-PCR product
in all dividing cells.

However, only a small portion of

the patients assayed exhibited a RT-PCR product

(21.7% of

patient samples in series A and 30.1% of patient samples in
series B ) , and only 60% of the control samples amplified
the correct hBC7B2-specific RT-PCR product.

Since part of

the PCR verification included the synthesis of the
complimentary DNA using a hBUBl oligonucleotide reverse PCR
primer, the lack of amplification was most likely not due
to incomplete cDNA synthesis.

However, a complex secondary

structure could have interfered with the cDNA synthesis
since the samples were not heated to eliminate secondary
structure prior to the reverse transcription reaction.
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Another explanation could be the presence of
hypermethylatdon within the hBUBl promoter region, which
may inhibit the expression of the gene.

The presence of an

actin RT-PCR product verifies that the overall RT-PCR
reaction was successful.

In addition, more control bone

marrow samples need to be assayed to obtain a more accurate
percentage of hBUBl-specific RT-PCR amplification.

The

investigation of the low amplification rate is deserving of
further research.

SEQUENCING RESULTS

If aneuploidy were caused by a mutation within a mitotic
spindle checkpoint gene, hBUBl would be a likely candidate
based on early literature.

Since hBUBl is required for the

spindle checkpoint within the cell cycle, the lack of hBUBl
function could hypothetically lead to the demise of the
spindle checkpoint and premature entrance into anaphase
before all chromosomes are properly aligned on the
metaphase plate.

It is also the most characterized of the

group of genes which comprises the mitotic spindle
checkpoint.
However, if a mutation in hBUBl did abrogate the function
of the mitotic spindle checkpoint, one would expect to see
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consistent levels of aneuploidy in all chromosomes.

It is

highly unlikely that a mutation in hBUBl would target a
specific chromosome,

thereby enabling chromosome-specific

aneuploidy to occur.

In this study, aneuploidy levels for

both chromosomes were not consistent.
With respect to the sequencing results obtained by this
study, it is reasonable to conclude that the base pair
changes seen after August 20, 1999 are not real, but are
due to artifacts introduced at the PCR stage of the
experiment.

Using this assumption, I modified the

presentation of the sequencing results

(Table 7).

In Table 7, I assumed that all base pair changes found in
patient samples analyzed after August 20, 1999 were
artifacts.

In addition,

I have removed all base pair

changes that did not result in an amino acid change

(as

this would probably not affect the function of the
protein).

This greatly reduces the number of potential

mutations due to actual base pair changes.
The sample from patient #43

(adjusted) shows the presence

of a base pair

change

at base pair 845, which is located

within the NLS

coding region (Cahill et a l ., 1999).

FISH

analysis failed to detect any significant amount of
aneuploidy for

either chromosome 7 or 8 for this patient.

Therefore, it is reasonable to conclude that the sample
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Table 7. Sequencing Results Adjusted for Taq-induc:ed PCR
Artifact
Patient # BP# BP Change
Amino Acid Change
43

845

G“>A

Glu">Lys

82

632
908

G~>A
C~>T

Gly~>Arg
Gln-^stop

132

566

A-»G

Thr-»Ala

136

731

A-»G

Lys~>Glu

Corrected sequence results for patient samples in s eries A
and series B. All samples listed were sequenced pr ior to
August 20, 1999 and had a base pair change that res'ulted in
an amino acid change. Note that none of the above
sequencing results were confirmable.
Abbreviation: BP=base pair
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from patient 43 either 1) had no mutations within the CD1
or NLS regions of hBUBl

(existing base pair change is an

artifact), 2) the base pair change present does not alter
the function of the BUB1 protein, or 3) hBUBl does not play
a direct role in the creation of aneuploidy.
The sample from patient #82 shows two base pair changes,
located at base pairs 632 and 908, both of which are
located in the NLS region.

If the base pair change at

number 908 were real, it would induce the formation of a
stop codon.

This would lead to the translation of a

truncated protein, which may be unable to function.

A

mutation in the NLS region may affect the ability of the
BUB1 protein to localize to the nucleus.
active at the kinetochore,

Since BUB1 is

it must be able to travel into

the nucleus from the cytoplasm to be able to function.
this patient sample,

In

statistically significantly elevated

levels of aneuploidy were not observed for either
chromosome 7 or 8.

In addition, the majority of the

sequence data obtained for the sample from patient 82
showed no base pair changes present.

It is therefore

reasonable to conclude that due to the high probability of
Taq-induced PCR artifact and because this patient did not
exhibit any signs of a loss of the mitotic spindle
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checkpoint (the appearance of aneuploidy), the base pair
changes seen are most likely artifactual.
Samples from patients #132 and #136 did not undergo FISH
analysis.

Regardless,

it is possible to draw similar

conclusions with respect to the sequencing results from
these patient samples, and assume that the base pair
changes seen are most likely the result of Taq-induced PCR
artifact.
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CHAPTER V
CONCLUSIONS

1. New FISH data on A A patient samples
This study showed that aneuploidy in patients with
aplastic anemia is a rare event, with only 7 of 46

(15.2%)

patient samples displaying aneuploidy for chromosome 7
and/or 8.

It is of importance to note that the percent

occurrence may not be synonymous with the percent of new
cytogenetic events, as clonal selection may play a role in
the expansion of a cell type.

It is possible that the

aneuploidy detected represents early clonal selection for
the apparent cytogenetic abnormalities, which may increase
over time.

2. FISH was approximately twice as sensitive as
conventional cytogenetic analysis by karyotype
In this study, FISH detected more than twice as many
cytogenetic abnormalities than the karyotype analysis.
FISH may be beneficial in detecting early cytogenetic
abnormalities.
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3. African-American males showed a statistically
significantly elevated level of monosomy 8
In. a multivariate ANOVA statistical analysis, AfricanAmerican males showed a greater likelihood of exhibiting
monosomy 8 (p=0.016) .

These results should be viewed with

caution due to the low sample size number, but may be
beneficial in the future if perhaps African-American males
have a genetic variant making them more susceptible to
developing AA.

4. One patient showed statistically significantly elevated
levels of aneuploidy for both chromosomes 7 and 8
One patient sample exhibited high levels of aneuploidy
for both chromosomes 7 and 8, which is more characteristic
of a CIN phenotype.

However, this appears to be a rare

occurrence within patients with AA.

5. Two patients showed the presence of an unusual insertion
within the forward primer area of hBUBl
Two patients

(#42 and #52) exhibited an insertion within

the forward primer area in hBUBl, which would be predicted
to inhibit the complete translation of the protein product.
If verified, these insertions would suggest a loss of
normal hBUBl function, and perhaps an abrogated mitotic
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spindle checkpoint.

Verification is needed to ensure that

the insertions are not due to faulty ligation with the
plasmid vector or errors with the polymerase activity.

The

sample from patient #52 did show a statistically
significantly elevated of aneuploidy, however the
aneuploidy does not appear to be due to the insertion, as
it would likely been seen in both patient samples.

6. Preliminary sequencing results indicated that base pair
changes in hBUBl within A A patients are rare occurrences
The majority of patient samples did not exhibit any true
base pair changes within the hBUBl CD1 and NLS regions.
This correlates to recent data from other laboratories
showing that mutations in hBUBl in a variety of cancers and
cancer cell lines rarely occur. This suggests that the
aneuploidy seen in these patient samples and in other
studies may not be due to a mutation within the mitotic
spindle checkpoint gene hBUBl.

However, there are many

possible causes of aneuploidy, with mutations in a mitotic
spindle checkpoint gene being only one of the different
pathways.

Further investigation and verification is

required to establish a more concrete conclusion.
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no
no
no
no
no
no
no

tetla R-cDKA. 7(1) 7(2) 7(3) 8(1) 8(2) 8(3)

+
+
+
+
+
+

-

+
+

+
-

n/a
+
+
n/a
n/a
n/a
+
+
+
+
n/a
+
n/a
+
+
+
n/a
+
+
+
+
+
+
+

n/a
n/a
n/a
n/a
+
n/a
n/a
+
-tn/a
-l+
+

+

-

+
+
+
+

-

+
+

-

+
+

-

+
+
+
+

-

+

-

Treatment

new; evaluate for ATG
new, evaluate for ATG
1 yr f/u non-responsive to ATG

failed ATG
new patient. No treatment
new patient. No treatment
EPO/G-CSF nonrespomder 1 yr ago

4

294

2

2

295

3 Cytoxan/CSA responder
post liver transplant. No treatment

4 296

0

10

289

3

1

11

289

296

1 no treatment
Danzol recently
0 ATG/CSA Relapased on CSA
None?
Treated with ATG & CSA
6mo f/u Post ATG non-responder

9 291

0

7

292

1

6mo f/u Post cytotox±n?/CSA

Responder

1 yr f/u failed ATG
2 297
10 287
3 295
8 292
9 289

1
3
1
0
2

7
7
5
4
7

289
291
293
295
290

8 290

2

1 238

5 yr f/u post ATG/CSA responder

4
2 6 yr f/u on CSA post ATG/CSA relapsed
platelet fx dependent?, ATG, 1L-3,
2 CSA
Neuoooem?
4
years
post ATG/CSA responder
1
3 ATG no response
no treatment
new
new
new ?- NR
new
none
ATG/CSA, on ? CSA
ATG/CSA responder
61 ATG/CSA responder now relapsed
ATG/CSA responder
ATG/CSA non-responder
ATG/CSA responder
Growth factor non responder

7 292
6 294

1
0

4 293
16 284

5 295

0

9 289

3 ATG,CSA.De??responder
0 no treatment
no treatment
2 2yr post A T G / C S A respomder
Failed ATG
Failed 5-A Z A Failed Neumega?

never treated
4

295

1

6 292

2

ATG/CSA iyr post tr. On CSA relapsed

ATG/CSA responder lyr
None
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67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
105
106
107
108
109
110
111
112

BUB
no
no
no
no
no
1.2
no
no
no
no
no
no
no
1.2
no
1.2
no
1.2
no
no
no
no
no
1.2
no
no
no
no
no
1.2
no
no
no
no
no
1.2
no
no
no
no
1.2
no
1.2
no
no

R-cDMA. 7(1) 7(2) 7(3) 8(1) 8(2) 8(3)
+

-

+

-

+
neg
+

-

+

+

+

-

neg

-

+

-

+

-

+

-

-

-

+

-

neg
n/a

n/a

+

-

n/a

n/a

5 295

0

4 294

-

n/a

n/a

+

-

+

-

+
+
+
n/a
n/a

n/a
n/a

+

-

+

-

neg

-

+

-

n/a
neg
+
+
neg
+
n/a
+
+
+
+
n/a
+
n/a
+
+

n/a

7 293
9 290

0
1

3
2
7
6

2
1
0
0

295
297
293
294

7 291
4 292

7
5
11
6

284
294
284
290

CSA

and

Prednisone

& EPO

None
2 None
4 6 months post ATG/CSA
None
ATG
8 CSA
0 1 year post cytoxen, 2 years post ATG
5 ATG/CSA 6 mo post tx, non responder
4 ATG/CSA 6 mo post tx, responder
ATG/CSA,

5 293

2

0 297

5

294

1

1

7 292
2 298

1
0

4 289
8 204

8 292

0

298

-

n/a
n/a
n/a
-

2

transient responder to ATG, s/p CSA —
-> MR
ATG responder then relapse, retreat
ATG — > normal counts

-

+

Treatment

lyr post ATG
None
6mo post cyotoxin?/CSA
yr f/u ??
None
None
ATG/CSA Relapsed
ATG Responder
None
None

10

286

Davarol, non responder

3 none
l.Oyr F/U ATG,
never treated
never treated
chemotherapy
1 18mo post ATG/CSA responder
none
none
7 lyear post cytoxen/CSA
88 1 1/2 year post ATG/CSA
nonresponder 10/95
4 6mo post ATG/CSA non responder
6mo

f/u

non

responder ATG

failed - new MDS
ATG/CSA responder - now cts dropping

no treatment
no treatment - to start CSA today

12

286

2

13

279

no treatment
failed ATG 1 year f/u
none
8 none
none
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R-cDKA

BOB

113 no
114 no
115 no
116 no
117 1.2
118 1.2
119 no
120 1.2
121 1.2
122 no
123 no
124 1.2
125 1.2
126 1.2
127 no
128 no
129 1.2
130 no
131 no
132 1.2
133 1.2
134 1.2
135 1.2
136 1.2
137 1.2
138 1.2
139 no
140 1.2
141 1.2
142 no
143 no
144 1.2
145 no
146 no
147 no
148 1.2
149 1.2
150 no
151 no
152 no
153 1.2
154 no
155 1.2
156 1.2
157 no

+
+
+
+
n/a
n/a
+
n/a
n/a
+
+
+
+
+
+
+
+
+
+
n/a
n/a
+
+
n/a
n/a
+
+
n/a
n/a
+
+
+
+
+
+
+
+
+
+
+
+
+
+
n/ a
+

7(1) 7(2) 7(3) 8(1) 8(2) 8(3)

n/a
n/a
n/a
n/a
,
+
+
+
+
n/a
n/a
+
+
n/a
n/a
+
n/a
n/a
+
+
+
+
+
n/a
-

3

254

2

7

3 296
8 289
8 292

1
3
0

4 292
3 287
9 288

7 293

0

5

251

294

T r ea t m e n t

1 none
multiple Amifostine etc
lyr post tr. Responder,
4 ATG/CSA
relaose now?
10 not treated
3 ATG/CSA relapsed currently on CSA
never treated
None
Untreated
1 ATG/CSA 6 mo ago, responder
1 yr ago Cytoken/CSA, responder

none
n ew patient. No treatment
n ew patient. No treatment
n ew patient. No treatment

none
6 110
2 296
4 161

0
1
0

14
0
2

100
299
163

IVIG, Steroids, spleenectomy
2
0 none
0 ATG/CSA responder
EEO
ATG 6mo post on FK506
6mo f/u CSA
EPO
ATG,

Relapsed 1 1/2 years non-responder,
ATG/CSAx2
ATG/CSA relapsed, CSA dependent

7

292

1

6

287

1 299

0

2

297

1 298

1

8 292

7 none
none
1 ATG/CSA Relapsed on CSA
new patient. No treatment
6yr, post ATG/CSA
new
patient. No treatment
0
Untreated
Cytoxan/CSA
Resoonder

4
4

295
296

1
0

3 291
8 290

1

297

2

8 291

3 297

0

6 294

I yr post treatment

None
6 new patient. No treatment
2 new patient. No treatment
new patient. No treatment
new patient. No treatment
ATG non-responder
new patient. No treatment
new patient. No treatment
1 new patient. No treatment
new patient. No treatment
6 mo f/u CSA responder
EPO
lyr post cytoxen/csa, 6mo post
0 ATG/CSA,
no response for both
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BOB

158 1.2
159 no
160 no
161 no
162 no
163 no
164 no
165 no
166 no
167 no
168 no
169 no
170 1.2
171 no
172 no
173 1.2
174 no
175 no
176 no
177 1.2
178 1.2
179 1.2
180 1.2
181 no
182 no
183 1.2
184 no
185 no
186 no
188 no
190 no
191 1.2
192 no
193 1.2
194 no
195 no
196 1.2
197 no
198 no
199 no
200 no
201 no
202 1.2
203 no
204 no

tuntin R-cDHA. 7(1) 7(2) 7(3) 8(1) 8(2) 8(3)

+
+
+
+
+

+
-

+

-

+

-

+
+
+
+
+
n/a
+

n/a
-

+
+
+
+

+
-

n/a

n/a

+
+
+
+
+
+
+
+
+
+
+

+
+
+
+
+
-

n/a
n/a

n/a
n/a

+

-

n/a

n/a

+
+

-

n/a

n/a

+
+
+
+
+
+
+
+

+
-

Treatment

11 years post treatment
none
none
7 years, none
ATG/CSA non—responder
ATG/CSA on ATG
N Bupogen
ATG/CSA 8 years post responder,
hepatitis C

9 290

5 295
5 295
2 298

1
0
0
0

4

296

8 291
12 257
3 294

0 new patient, no treatment

1 ATG/Decadurobulie? ?
31 ATG/CSA
3 ATG/CSA, cytotoxin
none
new patient, no treatment
new patient, no treatment
none
none
1 year post Cytoxan/CSA
ATG/CSA x2
none
none
ATG/CSA non—responder
ATG/CSA x3 approx 1 year from ATG
responder

none
ATG/CSA
Cytotoxin non—responder
none
ATG/CSA
none
none
none
ATG/ c S A 1 year post treatment

none
none

ATG failed
ATG failed
None
6 yrs post ATG/CSA Resp o n d e r
Cytoxan?CSA 6.5mo response?

None
ATG/CSA
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205
206
207
208
209
210
211
212

B O B festia R-ormx 7(1) 7(2) 7(3) 8(1) 8(2) 8(3)

1.2
no
no
no
no
no
no
no

n/a

n/a

+
+
+
+
+

-

Treatment

-

n/a

n/a

+

-

ATG/CSA

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

154

VITA
Name
Home Address
Telephone

Laura Jane Aridgides
330 West Brambleton Ave., #312
Norfolk, Virginia 23510
(757) 627-5176

UNIVERSITY EDUCATION
Undergraduate Bachelor of Science, Honors College, May 1997
Old Dominion University, Norfolk, Virginia
Postgraduate

Doctor of Philosophy, May 2001
Pure and Applied Biomedical Science, Old
Dominion University and Eastern Virginia
Medical School, Norfolk, Virginia

RESEARCH APPOINTMENTS
October 1999-Present: Graduate Research Assistant, Center
for Pediatric Research, Eastern Virginia Medical School
December 1998-September 1999: Research Assistant, Center
for Pediatric Research, Eastern Virginia Medical School
May 1997-December 1998: Research Assistant, Center for
Pediatric Research, Eastern Virginia Medical School and
Old Dominion University
January 1997-May 1997: Undergraduate Research Assistant,
Department of Biology, Old Dominion University
TEACHING RESPONSIBILITIES
August 1997-December 1998: Graduate Teaching
Assistant, Department of Chemistry and Biochemistry,
Old Dominion University, Dr. Robert L. Ake,
supervisor.
Summer 1998: Graduate Teaching Assistant, Department
of Chemistry and Biochemistry, Old Dominion
University, Dr. Roy Williams, supervisor
PUBLICATIONS
Hynes W.L., Dixon A.R., Walton S.L., and Aridgides L.J.
(2000). The extracellular hyaluronidase gene (hylA) of
Streptococcus pyogenes. FEMS Microbiol Lett 184(1), 109-12.
Aridgides, L.J., Stacey, M., Brihn, L., Scott, D., Osgood,
C., and Kearns, W.G. (2001). Fluorescence in situ
hybridization on fresh bone marrow cells and sperm using
alkaline denaturation. Biotechniques. (Submitted).

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

